



Europäisches Patentamt

European Patent Office

Office européen des brevets



(11) EP 1 512 744 A1

(12)

EUROPEAN PATENT APPLICATION

published in accordance with Art. 158(3) EPC

- (43) Date of publication: 09.03.2005 Bulletin 2005/10
- (21) Application number: 03733346.5
- (22) Date of filing: 10.06.2003

- (51) Int CI.7: C12N 15/12, C12N 1/21, C12N 5/10, C07K 14/435, C07K 19/00, G01N 21/78
- (86) International application number: PCT/JP2003/007336
- (87) International publication number: WO 2003/104460 (18.12.2003 Gazette 2003/51)
- (84) Designated Contracting States:

 AT BE BG CH CY CZ DE DK EE ES FI FR GB GR
 HU IE IT LI LU MC NL PT RO SE SI SK TR

 Designated Extension States:

 AL LT LV MK
- (30) Priority: 10.06.2002 JP 2002168583
- (71) Applicants:
 - Riken
 - Wako-shi, Saitama 351-0198 (JP)
 - Medical & Biological Laboratories Co., Ltd. Nagayo-shi, Aichi 460-0002 (JP)

- (72) Inventors:
 - MIYAWAKI, Atsushi
 Wako-shi, Saitama 351-0198 (JP)
 - KARASAWA, Satoshi, Medical & Biol. Labs.Co.,Ltd. Ina-shi, Nagano 396-0002 (JP)
- (74) Representative:
 Sternagel, Fleischer, Godemeyer & Partner
 Patentanwälte,
 An den Gärten 7
 51491 Overath (DE)

(54) PIGMENT PROTEIN

- (57) An object of the present invention is to provide a novel chromoprotein derived from *Cnidopus japonicus*. The present invention provides a chromoprotein derived from *Cnidopus japonicus* having the following properties:
 - (1) the absorption maximum wavelength is 610 nm, and fluorescence is not emitted;
- (2) the molar absorption coefficient is 66,700 at 610 nm; and
- (3) the pH sensitivity of light-absorbing property is stable at between pH 4 and pH 10.

Description

TECHNICAL FIELD

[0001] The present invention relates to a novel chromoprotein. More specifically, the present invention relates to a novel chromoprotein derived from *Cnidopus japonicus*, and the use thereof.

BACKGROUND ART

[0002] Green fluorescent protein (GFP) derived from Aequorea victoria, a jellyfish, has many purposes in biological systems. Recently, various GFP mutants have been produced based on the random mutagenesis and semi-rational mutagenesis, wherein a color is changed, a folding property is improved, luminance is enhanced, or pH sensitivity is modified. Fluorescent proteins such as GFP are fused with other proteins by gene recombinant technique, and monitoring of the expression and transportation of the fusion proteins is carried out.

[0003] One of the most commonly used types of GFP mutant is Yellow fluorescent protein (YFP). Among Aequoreaderived GFP mutants, YFP exhibits the fluorescence with the longest wavelength. The values ε and Φ of the majority of YEPs are 60,000 to 100,000 M⁻¹cm⁻¹ and 0.6 to 0.8, respectively (Tsien, R. Y. (1998). Ann. Rev. Biochem. 67, 509-544). These values are comparable to those of the general fluorescent group (fluorescein, rhodamine, etc.). Accordingly, improvement of the absolute luminance of YFP is nearly approaching its limit.

[0004] In addition, cyan fluorescent protein (CFP) is another example of the GFP mutant. Of this type of protein, ECFP (enhanced cyan fluorescent protein) has been known. Moreover, red fluorescent protein (RFP) has been isolated from sea anemone (*Discoma sp.*). Of this type of protein, DasRed has been known. Thus, 4 types of fluorescent proteins, that are, green fluorescent protein, yellow fluorescent protein, cyan fluorescent protein, and red fluorescent protein, have successively been developed. The range of the spectrum has significantly been expanded.

DISCLOSURE OF THE INVENTION

[0005] An object of the present invention is to provide a novel chromoprotein derived from *Cnidopus japonicus*.

[0006] The present inventors have conducted intensive studies directed towards achieving the aforementioned object. They have designed suitable primers based on information regarding the amino acid sequences of known fluorescent proteins. Using these primers, they have succeeded in the amplification and cloning of a gene encoding a novel chromoprotein from the cDNA library of *Cnidopus japonicus* exhibiting a green color. The present inventors have further analyzed the light-absorbing properties and pH sensitivity of the obtained chromoprotein derived from *Cnidopus japonicus*. The present invention has been completed based on these findings.

[0007] That is to say, the present invention provides a chromoprotein derived from *Cnidopus japonicus* having the following properties:

- (1) the absorption maximum wavelength is 610 nm, and fluorescence is not emitted;
- (2) the molar absorption coefficient is 66,700 at 610 nm; and
- (3) the pH sensitivity of light-absorbing property is stable at between pH 4 and pH 10.

[0008] In another aspect, the present invention provides a chromoprotein having either one of the following amino acid sequences:

- (a) the amino acid sequence shown in SEQ ID NO: 1; and
- (b) an amino acid sequence comprising a deletion, substitution and/or addition of one or several amino acids with respect to the amino acid sequence shown in SEQ ID NO: 1, and having light-absorbing properties.

[0009] In another aspect, the present invention provides a chromoprotein capable of emitting fluorescence, which has an amino acid sequence, wherein, with respect to the amino acid sequence shown in SEQ ID NO: 1, alanine as an amino acid residue at position 28 is substituted by glycine, glutamic acid as an amino acid residue at position 41 is substituted by methionine, cysteine as an amino acid residue at position 145 is substituted by serine, and threonine as an amino acid residue at position 158 is substituted by isoleucine.

[0010] In another aspect, the present invention provides:

a chromoprotein having an amino acid sequence wherein tyrosine as an amino acid residue at position 64 is substituted by leucine with respect to the amino acid sequence shown in SEQ ID NO: 1;

a chromoprotein having an amino acid sequence wherein tyrosine as an amino acid residue at position 64 is

substituted by methionine with respect to the amino acid sequence shown in SEQ ID NO: 1;

a chromoprotein having an amino acid sequence, wherein glutamic acid as an amino acid residue at position 41 is substituted by leucine, and phenylalanine as an amino acid residue at position 80 is substituted by glycine, with respect to the amino acid sequence shown in SEQ ID NO: 1:

a chromoprotein capable of emitting fluorescence, which has an amino acid sequence wherein tyrosine as an amino acid residue at position 64 is substituted by phenylalanine with respect to the amino acid sequence shown in SEQ ID NO: 1;

a chromoprotein capable of emitting fluorescence, which has an amino acid sequence wherein tyrosine as an amino acid residue at position 64 is substituted by histidine with respect to the amino acid sequence shown in SEQ ID NO: 1; and

a chromoprotein capable of emitting fluorescence, which has an amino acid sequence, wherein cysteine as an amino acid residue at position 26 is substituted by valine, cysteine as an amino acid residue at position 143 is substituted by serine, and proline as an amino acid residue at position 199 is substituted by leucine, with respect to the amino acid sequence shown in SEQ ID NO: 1.

[0011] In another aspect, the present invention provides DNA encoding the protein of the present invention.[0012] In another aspect, the present invention provides either one of the following DNAs:

- (a) DNA encoding the amino acid sequence shown in SEQ ID NO: 1; and
- (b) DNA encoding an amino acid sequence, which comprises a deletion, substitution and/or addition of one or several amino acids with respect to the amino acid sequence shown in SEQ ID NO: 1, and has light-absorbing properties.

[0013] In another aspect, the present invention provides DNA having either one of the following nucleotide sequences:

- (a) the nucleotide sequence shown in SEQ ID NO: 2; and
- (b) a nucleotide sequence comprising a deletion, substitution and/or addition of one or several nucleotides with respect to the nucleotide sequence shown in SEQ ID NO: 2, and encoding a protein having light-absorbing properties.

[0014] In another aspect, the present invention provides DNA having the nucleotide sequence shown in any one of SEQ ID NOS: 12, 14, 16, 18, 20, or 22.

[0015] In another aspect, the present invention provides a recombinant vector having the DNA of the present invention.

[0016] In another aspect, the present invention provides a transformant having the DNA or recombinant vector of the present invention.

[0017] In another aspect, the present invention provides a fusion protein composed of the chromoprotein of the present invention and another protein.

[0018] In another aspect, the present invention provides a method for analyzing a physiologically active substance, which is characterized in that the FRET (fluorescence resonance energy transfer) method is applied using the chromoprotein of the present invention as an acceptor protein.

[0019] In another aspect, the present invention provides a light-absorbing reagent kit comprising the chromoprotein, DNA, recombinant vector, transformant, or fusion protein of the present invention.

BRIEF DESCRIPTION OF THE DRAWINGS

[0020]

25

35

Figure 1 shows the results obtained by measuring the absorption spectrum of the chromoprotein (KGr) derived from *Cnidopus japonicus* of the present invention. The transverse axis indicates the wavelength of absorbed light, and the vertical axis indicates absorbance.

Figure 2 shows the pH sensitivity of the absorption spectrum of the chromoprotein (KGr) derived from *Cnidopus japonicus* of the present invention. The transverse axis indicates pH value, and the vertical axis indicates absorbance. 610 nm indicates the absorbance that is specific to the chromoprotein (KGr) derived from *Cnidopus japonicus* of the present invention, and 277 nm indicates the absorbance (light absorption by aromatic amino acids) that is generally used as a quantitative amount of protein. In other words, it is shown that the amount of protein is constant at 277 nm, and the absorbance at 610 nm that is specific to the chromoprotein (KGr) derived from *Cnidopus*

japonicus of the present invention hardly changes in the range between pH 4 and pH 10.

Figure 3 shows the fluorescence spectrum of a mutant of the chromoprotein (KGr) derived from *Cnidopus japonicus* of the present invention (a mutant obtained by substituting A at position 28 by G, substituting E at position 41 by M, substituting C at position 145 by S, and substituting T at position 158 by I in the amino acid sequence of KGr). The transverse axis indicates wavelength, and the vertical axis indicates fluorescence intensity. The term "em" indicates a fluorescence spectrum, and the term "ex" indicates an excitation spectrum.

Figure 4 shows the absorption spectrum of a mutant of the chromoprotein (KGr) derived from *Cnidopus japonicus* of the present invention (a mutant obtained by substituting Y at position 64 by L in the amino acid sequence of KGr). Figure 5 shows the absorption spectrum of a mutant of the chromoprotein (KGr) derived from *Cnidopus japonicus* of the present invention (a mutant obtained by substituting Y at position 64 by M in the amino acid sequence of KGr). Figure 6 shows the absorption spectrum of a mutant of the chromoprotein (KGr) derived from *Cnidopus japonicus* of the present invention (a mutant obtained by substituting E at position 41 by L and substituting F at position 80 by G in the amino acid sequence of KGr).

Figure 7 shows the fluorescence and excitation spectrums of a mutant of the chromoprotein (KGr) derived from *Cnidopus japonicus* of the present invention (a mutant obtained by substituting Y at position 64 by F in the amino acid sequence of KGr).

Figure 8 shows the absorption spectrum of a mutant of the chromoprotein (KGr) derived from *Cnidopus japonicus* of the present invention (a mutant obtained by substituting Y at position 64 by F in the amino acid sequence of KGr). Figure 9 shows the fluorescence and excitation spectrums of a mutant of the chromoprotein (KGr) derived from *Cnidopus japonicus* of the present invention (a mutant obtained by substituting Y at position 64 by H in the amino acid sequence of KGr).

Figure 10 shows the absorption spectrum of a mutant of the chromoprotein (KGr) derived from *Cnidopus japonicus* of the present invention (a mutant obtained by substituting Y at position 64 by H in the amino acid sequence of KGr). Figure 11 shows the fluorescence and excitation spectrums of a mutant of the chromoprotein (KGr) derived from *Cnidopus japonicus* of the present invention (a mutant obtained by substituting C at position 26 by V, substituting C at position 143 by S, and substituting P at position 199 by L in the amino acid sequence of KGr).

Figure 12 shows the absorption spectrum of a mutant of the chromoprotein (KGr) derived from *Cnidopus japonicus* of the present invention (a mutant obtained by substituting C at position 26 by V, substituting C at position 143 by S, and substituting P at position 199 by L in the amino acid sequence of KGr).

BEST MODE FOR CARRYING OUT THE INVENTION.

[0021] The embodiments of the present invention will be described in detail below.

(1) Chromoprotein of the present invention

[0022] The chromoprotein of the present invention is characterized in that it is derived from *Cnidopus japonicus*, and has the following properties:

- (1) the absorption maximum wavelength is 610 nm, and fluorescence is not emitted;
- (2) the molar absorption coefficient is 66,700 at 610 nm; and
- (3) the pH sensitivity of light-absorbing property is stable at between pH 4 and pH 10.

[0023] Cnidopus japonicus is one type of sea anemone belonging to Anthozoa of Cnidaria. Among the types of sea anemone that can be seen in Japan, Cnidopus japonicus has the highest degree of color mutation. Its withers height is always low, and it has a large number of warts on the body wall thereof. It has approximately 200 short tentacles. A parent sea anemone discharges developed embryos from its oral part. The discharged embryos become attached to the body wall of the parent sea anemone. Thereafter, the embryos are further developed, and as a result, they become baby sea anemone. Thus, this sea anemone was named Komochi Isoginchaku (a Japanese name meaning "seed sea anemone"). This type of sea anemone is distributed in the intertidal zones on the rock coasts between Hokkaido and Boso Peninsula and also in the zones immediately below the intertidal zones.

[0024] It is to be noted that a chromoprotein having the aforementioned properties was isolated using *Cnidopus japonicus* as a starting material in the examples described later, but that the chromoprotein of the present invention may also be obtained from forms of sea anemone other than *Cnidopus japonicus* in some cases. Such a chromoprotein is also included in the scope of the present invention.

[0025] As described in the examples below, the chromoprotein of the present invention has an absorption maximum wavelength of 610 nm and does not emit fluorescence. In addition, the present chromoprotein has a molar absorption coefficient of 66,700 at 610 nm. The molar absorption coefficient represents the amount of absorbed photons per mole

20

of molecule. Since the chromoprotein of the present invention does not emit fluorescence, the chromoprotein of the present invention can be used: (1) as an acceptor molecule (energy receptor) in FRET; (2) in development of a system for converting the energy of applied light into energy other than the light; and (3) in introduction of a mutation into the amino acid sequence of the protein to modify it so that it emits fluorescence.

[0026] In addition, the chromoprotein of the present invention is characterized in that the pH sensitivity of light-absorbing properties is stable at between pH 4 and pH 10. That is to say, in the case of the chromoprotein of the present invention, the peak value of the absorption spectrum does not significantly fluctuate in the range between pH 4 and pH 10. Accordingly, even under the same conditions, the chromoprotein of the present invention can be used in a broad range of pH environments, and thus, the use of the chromoprotein in vivo has few restrictions.

[0027] The examples of the chromoprotein of the present invention include a chromoprotein having either one of the following amino acid sequences:

- (a) the amino acid sequence shown in SEQ ID NO: 1; and
- (b) an amino acid sequence comprising a deletion, substitution and/or addition of one or several amino acids with respect to the amino acid sequence shown in SEQ ID NO: 1, and having light-absorbing properties.

[0028] The scope of "one or several" in the phrase "an amino acid sequence comprising a deletion, substitution and/ or addition of one or several amino acids" is not particularly limited in the present specification. For example, it means 1 to 20, preferably 1 to 10, more preferably 1 to 7, further preferably 1 to 5, and particularly preferably 1 to 3.

[0029] The term "light-absorbing properties" is used in the present specification to mean properties capable of absorbing light having a certain wavelength. For example, an absorption maximum wavelength may be 610 nm as in the case of the chromoprotein described in the present specification, or the value of the absorption maximum wavelength may also be shifted. It is preferable that the pH sensitivity of light-absorbing properties is stable at between pH 4 and pH 10.

[0030] The chromoprotein of the present invention having the amino acid sequence shown in SEQ ID NO: 1 in the sequence listing does not emit fluorescence. In the present invention, one or several amino acids are deleted, substituted, and/or added with respect to the amino acid sequence shown in SEQ ID NO: 1, so as to produce a protein having modified light-absorbing properties, or so as to produce a protein emitting fluorescence in some cases. The thus produced proteins are also included in the scope of the present invention.

[0031] A specific example of a fluorescent protein produced by such mutation of amino acids may be a fluorescent protein having an amino acid sequence, wherein, with respect to the amino acid sequence shown in SEQ ID NO: 1, alanine as an amino acid residue at position 28 is substituted by glycine, glutamic acid as an amino acid residue at position 41 is substituted by methionine, cystelne as an amino acid residue at position 145 is substituted by serine, and threonine as an amino acid residue at position 158 is substituted by isoleucine.

[0032] Other specific examples of a fluorescent protein produced by such mutation of amino acids may include: a chromoprotein having an amino acid sequence wherein tyrosine as an amino acid residue at position 64 is substituted by leucine with respect to the amino acid sequence shown in SEQ ID NO: 1; a chromoprotein having an amino acid sequence wherein tyrosine as an amino acid residue at position 64 is substituted by methionine with respect to the amino acid sequence shown in SEQ ID NO: 1; a chromoprotein having an amino acid sequence, wherein glutamic acid as an amino acid residue at position 41 is substituted by leucine, and phenylalanine as an amino acid residue at position 80 is substituted by glycine, with respect to the amino acid sequence shown in SEQ ID NO: 1; a chromoprotein capable of emitting fluorescence, which has an amino acid sequence wherein tyrosine as an amino acid residue at position 64 is substituted by phenylalanine with respect to the amino acid sequence shown in SEQ ID NO: 1; and a chromoprotein capable of emitting fluorescence, which has an amino acid sequence shown in SEQ ID NO: 1; and a chromoprotein capable of emitting fluorescence, which has an amino acid sequence, wherein cysteine as an amino acid residue at position 26 is substituted by valine, cysteine as an amino acid residue at position 143 is substituted by serine, and proline as an amino acid residue at position 5 is substituted by valine, cysteine as an amino acid residue at position 143 is substituted by serine, and proline as an amino acid residue at position 5 is substituted by valine, cysteine as an amino acid residue, with respect to the amino acid sequence shown in SEQ ID NO: 1.

[0033] The method of obtaining the chromoprotein of the present invention is not particularly limited. The protein may be either a protein synthesized by chemosynthesis, or recombinant protein produced by a gene recombination technique.

[0034] Where a recombinant protein is produced, it is necessary to obtain DNA encoding the protein. Appropriate primers are designed by using information regarding the amino acid sequence shown in SEQ ID NO: 1 of the sequence listing of the present specification and the nucleotide sequence shown in SEQ ID NO: 2 thereof. Using these primers, PCR is carried out by using cDNA library derived from *Cnidopus japonicus* as a template, so that DNA encoding the chromoprotein of the present invention can be obtained. The chromoprotein of the present invention can be produced by introducing this DNA into an appropriate expression system. Expression in an expression system will be described

later in the present specification.

(2) DNA of the present invention

[0035] According to the present invention, a gene encoding the chromoprotein of the present invention is provided. [0036] Specific examples of DNA encoding the chromoprotein of the present invention may include either one of the following DNAs:

- (a) DNA encoding the amino acid sequence shown in SEQ ID NO: 1; and
- (b) DNA encoding an amino acid sequence, which comprises a deletion, substitution and/or addition of one or several amino acids with respect to the amino acid sequence shown in SEQ ID NO: 1, and has light-absorbing properties.

[0037] Other examples of DNA encoding the chromoprotein of the present invention may include either one of the following DNAs:

- (a) the nucleotide sequence shown in SEQ ID NO: 2; and
- (b) a nucleotide sequence comprising a deletion, substitution and/or addition of one or several nucleotides with respect to the nucleotide sequence shown in SEQ ID NO: 2, and encoding a protein having light-absorbing properties.

[0038] Further, examples of the DNA having the nucleotide sequence comprising a deletion, substitution and/or addition of one or several nucleotides with respect to the nucleotide sequence shown in SEQ ID NO: 2, and encoding a protein having light-absorbing properties, may include DNA having the nucleotide sequence shown in any one of SEQ ID NOS: 12, 14, 16, 18, 20, or 22.

[0039] The DNA of the present invention can be synthesized by, for example, the phosphoamidite method, or it can also be produced by polymerase chain reaction (PCR) using specific primers. The DNA of the present invention is produced by the method described above in the specification.

[0040] A method of introducing a desired mutation into a certain nucleic acid sequence is known to a person skilled in the art. For example, known techniques such as a site-directed mutagenesis, PCR using degenerated oligonucleotides, or the exposure of cells containing nucleic acid to mutagens or radioactive rays, are appropriately used, so as to construct DNA having a mutation. Such known techniques are described in, for example, Molecular Cloning: A Laboratory Manual, 2nd Ed., Cold Spring Harbor Laboratory, Cold Spring Harbor, NY., 1989; and Current Protocols in Molecular Biology, Supplements 1 to 38, John Wiley & Sons (1987-1997).

(3) Recombinant vector of the present invention

[0041] The DNA of the present invention can be inserted into a suitable vector and used. The type of a vector used in the present invention is not particularly limited. For example, it may be either a vector that can autonomously replicate (e.g., a plasmid, etc.), or vector that is incorporated into the genomes of host cells when it is introduced into the host cells and is then replicated together with the chromosome into which it is incorporated.

[0042] The vector used in the present invention is preferably an expression vector. In an expression vector, elements necessary for transcription (e.g., a promoter, etc.) are functionally ligated to the DNA of the present invention. The promoter is a DNA sequence which shows a transcriptional activity in host cells, and it is appropriately selected depending on the type of host cells.

[0043] Examples of a promoter which can operate in bacterial cells may include a *Bacillus stearothermophilus* mattogenic amylase gene promoter, a *Bacillus licheniformis* alpha-amylase gene promoter, a *Bacillus amyloliquefaciens* BAN amylase gene promoter, a *Bacillus subtilis* alkaline protease gene promoter, a *Bacillus pumilus* xylosidase gene promoter, P_R and P_L promoters of phage rhamda, and lac, trp and tac promoters of

Escherichia coli.

[0044] Examples of a promoter which can operate in mammalian cells may include an SV40 promoter, an MT-1 (metallothionein gene) promoter, and an adenovirus-2 major late promoter. Examples of a promoter which can operate in insect cells may include a polyhedrin promoter, a P10 promoter, an *Autographa californica* polyhedrosis basic protein promoter, a baculovirus immediate-early gene 1 promoter, and a baculovirus 39K delayed-early gene promoter. Examples of a promoter which can be operate in yeast host cells may include promoters derived from yeast glycolytic genes, an alcohol dehydrogenase gene promoter, a TPI1 promoter, and an ADH2-4c promoter.

[0045] Examples of a promoter which can operate in filamentous cells may include an ADH3 promoter and a tpiA promoter.

[0046] In addition, an appropriate terminator such as a human growth hormone terminator, or a TPI1 terminator or ADH3 terminator for fungal cells, may be functionally bound to the DNA of the present invention, as necessary. The recombinant vector of the present invention may further have elements such as a polyadenylation signal (e.g., one derived from SV40 or the adenovirus 5E1b region), a transcription enhancer sequence (e.g., an SV40 enhancer), or a translation enhancer sequence (e.g., one encoding the adenovirus VA RNA).

[0047] The recombinant vector of the present invention may further comprise a DNA sequence which enables the replication of the recombinant vector in host cells. SV40 replication origin is an example of such a sequence (when the host cells are mammalian cells).

[0048] The recombinant vector of the present invention may further comprise a selective marker. Examples of such a selective marker may include genes, complements of which are absent from host cells, such as a dihydrofolate reductase (DHFR) gene or a *Shizosaccharomyces pombe* TPI gene, and drug resistant genes such as ampicillin, kanamycin, tetracycline, chloramphenicol, neomycin or hygromycin-resistant genes.

[0049] A method for ligating the DNA of the present invention, a promoter and, as desired, a terminator and/or a secretory signal sequence to one another and inserting these items into a suitable vector is known to a person skilled in the art.

(4) Transformant of the present invention

[0050] A transformant can be produced by introducing the DNA or recombinant vector of the present invention into a suitable host.

[0051] Any cell can be used as a host cell into which the DNA or recombinant vector of the present invention is introduced, as long as the DNA construct of the present invention can be expressed therein. Examples of such a cell may include bacteria, yeasts, fungal cells, and higher eukaryotic cells.

[0052] Examples of bacteria may include Gram-positive bacteria such as Bacillus or Streptomyces, and Gram-negative bacteria such as *Escherichia coli*. These bacteria may be transformed by the protoplast method or other known methods, using competent cells.

[0053] Examples of mammalian cells may include HEK 293 cells, HeLa cells, COS cells, BHK cells, CHL cells, and CHO cells. A method of transforming mammalian cells and expressing the introduced DNA sequence in the cells is also known. Examples of such a method may include the electroporation, the calcium phosphate method, and the lipofection method.

[0054] Examples of yeast cells may include those belonging to Saccharomyces or Shizosaccharomyces. Examples of such cells may include Saccharomyces cerevisiae and Saccharomyces kluyveri. Examples of a method of introducing a recombinant vector into yeast host cells may include the electroporation, the spheroplast method, and the lithium acetate method

[0055] Examples of other fungal cells may include those belonging to *Filamentous fungi* such as Aspergillus, Neurospora, Fusarium or Trichoderma. Where *Filamentous fungi* are used as host cells, transformation can be carried out by incorporating DNA constructs into host chromosomes, so as to obtain recombinant host cells. Incorporation of DNA constructs into the host chromosomes is carried out by known methods, and such known methods may include homologous recombination and heterologous recombination.

[0056] Where insect cells are used as host cells, both a vector into which a recombinant gene is introduced and a baculovirus are co-introduced into insect cells, and a recombinant virus is obtained in the culture supernatant of the insect cells. Thereafter, insect cells are infected with the recombinant virus, so as to allow the cells to express proteins (described in, for example, Baculovirus Expression Vectors, A Laboratory Manual; and Current Protocols in Molecular Biology, Bio/Technology, 6, 47 (1988)).

[0057] The Autographa californica nuclear polyhedrosis virus, which is a virus infecting to insects belonging to Barathra brassicae, can be used as baculovirus.

[0058] Examples of insect cells used herein may include Sf9 and Sf21, which are *Spodoptera frugiperda* ovarian cells [Baculovirus Expression Vectors, A Laboratory Manual, W. H. Freeman & Company, New York, (1992)], and HiFive (manufactured by Invitrogen), which are *Trichoplusia ni* ovarian cells.

[0059] Examples of the method of co-introducing both a vector into which a recombinant gene has been introduced and the above baculovirus into insect cells to prepare a recombinant virus may include the calcium phosphate method and the lipofection method.

[0060] The above transformant is cultured in an appropriate nutritive medium under conditions enabling the introduced DNA construct to be expressed. In order to isolate and purify the protein of the present invention from the culture product of the transformant, common methods of isolating and purifying proteins may be used.

[0061] For example, where the protein of the present invention is expressed in a state dissolved in cells, after com-

pletion of the culture, cells are recovered by centrifugal separation, and the recovered cells are suspended in a water type buffer. Thereafter, the cells are disintegrated using an ultrasonic disintegrator or the like, so as to obtain a cell-free extract. A supernatant is obtained by centrifuging the cell-free extract, and then, a purified sample can be obtained from the supernatant by applying, singly or in combination, the following ordinary protein isolation and purification methods: the solvent extraction, the salting-out method using ammonium sulfate or the like, the desalting method, the precipitation method using an organic solvent, the anion exchange chromatography using resins such as S-Sepharose FF (manufactured by Pharmacia), the hydrophobic chromatography using resins such as butyl sepharose or phenyl sepharose, the gel filtration method using a molecular sieve, the affinity chromatography, the chromatofocusing method, and the electrophoresis such as isoelectric focusing.

(5) Use of the chromoprotein of the present invention and a fusion protein comprising the same

[0062] The chromoprotein of the present invention can be fused with another protein, so as to construct a fusion protein. The type of said another protein to be fused to the chromoprotein of the present invention is not particularly limited, and preferred examples may include a protein which interacts with another molecule. The examples may include a receptor protein or ligand thereof, antigen, antibody and the like.

[0063] A method of obtaining the fusion protein of the present invention is not particularly limited. It may be either a protein synthesized by chemosynthesis, or recombinant protein produced by a gene recombination technique.

[0064] Where a recombinant fusion protein is produced, it is necessary to obtain DNA encoding the protein. The DNA encoding the chromoprotein of the present invention and the DNA encoding the another protein to be fused to the chromoprotein, can be obtained by the method as mentioned above in this specification or by the method similar to it. Then, these DNA fragments are ligated to one another by a gene recombination technique, so that DNA encoding the desired fusion protein can be obtained. This DNA is then introduced into an appropriate expression system, so that the fusion protein of the present invention can be produced.

[0065] FRET (fluorescence resonance energy transfer) has been known as a means for analyzing the interaction between molecules. In FRET, for example, a first molecule labeled with a cyan fluorescent protein (CFP) acting as a first fluorescent protein is allowed to coexist with a second molecule labeled with a yellow fluorescent protein (YFP) acting as a second fluorescent protein, so as to allow the yellow fluorescent protein (YFP) to act as an acceptor molecule and to allow the cyan fluorescent protein (CFP) to act as a donor molecule. Thus, FRET (fluorescence resonance energy transfer) is allowed to take place between both molecules, so as to visualize the interaction between the first and second molecules. Namely, in FRET, different dyes are introduced into two types of molecules. One dyes with a higher energy level (a donor molecule) is selectively excited, and the fluorescence of the dye is measured. Longwavelength fluorescence from the other dye (an acceptor molecule) is also measured. The interaction between the molecules is visualized by using the difference between the amounts of both fluorescences. Only when both dyes are adjacent to each other due to the interaction of the two types of molecules, a decrease in the fluorescence of the donor molecule and an increase in the fluorescence of the acceptor molecule are observed by single wavelength excitation dual wavelength photometry. However, in a case where a chromoprotein is used as an acceptor molecule, a decrease in the fluorescence of the donor molecule occurs only when both dyes are adjacent to each other by the interaction of the two types of molecules. Such a decrease can be observed by single wavelength excitation single wavelength photometry. Thus, the use of the chromoprotein of the present invention enables facilitation of measurement appara-

[0066] The chromoprotein of the present invention is particularly advantageous when it is used as an acceptor molecule in FRET (fluorescence resonance energy transfer). That is to say, a fused form (a first fused form) of the chromoprotein of the present invention and a test substance is first produced. Then, a fused form (a second fused form) of another test substance interacting with the above test substance and another fluorescent protein is produced. Thereafter, the first fused form is allowed to interact with the second fused form, and the generated fluorescence is analyzed, so that the interaction between the aforementioned two types of test substances can be analyzed. FRET (fluorescence resonance energy transfer) using the chromoprotein of the present invention may be carried out either in a test tube or in a cell.

(6) Kit of the present invention

[0067] The present invention provides a light-absorbing reagent kit comprising at least one which is selected from the chromoprotein, fusion protein, DNA, recombinant vector or transformant, which are described in the present specification. The kit of the present invention can be produced from commonly used materials that are known per se, by using common methods.

[0068] Reagents such as the chromoprotein or the DNA are dissolved in an appropriate solvent, so that the reagents

25

30

can be prepared in a form suitable for conservation. Water, ethanol, various types of buffer solution, etc. can be used as such a solvent.

[0069] The present invention will be further described in the following examples. However, the present invention is not limited by these examples.

EXAMPLES

Example 1: Isolation of gene encoding novel chromoprotein from sea anemone

(1) Extraction of total RNA

[0070] A chromoprotein gene was isolated from sea anemone emitting a green color. Cnidopus japonicus emitting a green color was used as a material. Frozen Cnidopus japonicus was crushed in a mortar. 7.5 ml of "TRIzol" (GIBCO BRL) was added to 1 g (wet weight) of Cnidopus japonicus, and the mixture was homogenized, followed by centrifugation at 1,500 \times g for 10 minutes. 1.5 ml of chloroform was added to the supernatant. The mixture was stirred for 15 seconds and then left at rest for 3 minutes. The resultant product was centrifuged at 7,500 \times g for 15 minutes. 3.75 ml of isopropanol was added to the supernatant. The mixture was stirred for 15 seconds and then left at rest for 10 minutes. The resultant product was centrifuged at 17,000 \times g for 10 minutes. The supernatant was discarded, and 6 ml of 70% ethanol was added thereto. The obtained mixture was centrifuged at 17,000 \times g for 10 minutes. The supernatant was discarded, and the precipitate was dissolved in 200 μ l of DEPC water. Total RNA dissolved in the DEPC water was 100 times diluted, and the values of 0.D.260 and 0.D.280 were measured, so as to determine the concentration of RNA. 1.2 mg of the total RNA was obtained from a green individual.

(2) Synthesis of first stand cDNA

[0071] cDNA (33 µl) was synthesized from 4 µg of the total RNA using a kit for synthesizing first strand cDNA, "Ready To Go" (Amersham Pharmacia).

(3) Degenerated PCR

[0072] Using 3 μ l out of the synthesized first strand cDNA (33 μ) as a template, PCR was carried out. Primers were designed and produced by comparing the amino acid sequences of known fluorescent proteins, extracting similar portions, and converting them into nucleotide sequences. The sequences of the used primers are shown below:

5'-GGIGSICCIHTISCITT-3' (primer 1) (SEQ ID NO: 3);

and

wherein I represents inosine, S represents C or G, and H represents A, T, or C.

Composition of PCR reaction s	olution'
Template (first strand cDNA)	3 μΙ
X 10 taq buffer	5 μl
2.5 mM dNTPs	.4 μ1
100 uM primer 3	1 μΙ
100 uM primer 4	1 μΙ
Milli Q	35 µl
Taq polymerase (5 U/μΙ)	1 μΙ

RCR reaction conditions

94°C, 1 minute (PAD)

94°C, 30 seconds (denaturation)

52°C, 30 seconds (annealing of the primers to the template)

72°C, 1 minute (elongation of the primers)

[0073] 30 cycles consisting of the above 3 steps were carried out. The annealing temperature was decreased 0.3°C per cycle. That is to say, the annealing temperature in the 30th cycle was 43°C.

72°C, 7 minutes (final elongation)

Retention at 4°C

[0074] Using 1 μ I of an amplified product obtained as a result of the first PCR reaction as a template, PCR was carried out once again under the same conditions. A 800-bp fragment (derived from the green individual) was cut out by agarose gel electrophoresis and then purified. This 800-bp fragment contained a 3'-UTR portion as a whole.

(4) Subcloning and sequencing

[0075] The purified DNA fragment was ligated to a pT7-blue vector (Novagen). Escherichia coli (TG1) was transformed with the vector, and the obtained transformants were subjected to blue white selection. Thereafter, plasmid DNA was purified from white colonies of Escherichia coli. The nucleotide sequence of the inserted DNA fragment was determined by a DNA sequencer. The obtained nucleotide sequence was compared with the nucleotide sequences of other fluorescent protein genes to confirm that the nucleotide sequence of the DNA was derived from a fluorescent protein. 5'-RACE and 3'-RACE methods were applied to a gene that had been confirmed to be a part of a fluorescent protein gene, so as to carry out the cloning of a full-length gene.

(5) 5'-RACE method

[0076] In order to determine the nucleotide sequence of the 5'-terminal side of the DNA fragment obtained by degenerated PCR, the 5'-RACE method was applied using 5'-RACE System for Rapid Amplification of cDNA Ends, Version 2.0 (GIBCO BRL). $3 \mu g$ of the total RNA prepared in (1) above was used as a template.

[0077] For the first amplification of DC-tailed cDNA of the green individual, the following primers were used:

5'-GGCCACGCGTCGACTAGTACGGGIIGGGIIGGGIIG-3' (primer 3) (SEQ ID NO:

5);

and

5'-AGACGAGGCAATTTCCATCAAG-3' (primer 4) (SEQ ID NO: 6),

wherein I represents inosine.

[0078] For the second amplification, the following primers were used:

5'-GGCCACGCGTCGACTAGTAC-3' (primer 5) (SEQ ID NO: 7);

and

5'-GGCTACGCTTCCATATTGGCAGTT-3' (primer 6) (SEQ ID NO: 8).

PCR reaction conditions and the like were determined in accordance with the protocols attached with the kit.

[0079] The 350-bp amplified band was cut out by agarose gel electrophoresis and then purified. The purified DNA fragment was ligated to a pT7-blue vector (Novagen). Escherichia coli (TG1) was transformed with the vector, and the obtained transformants were subjected to blue white selection. Thereafter, plasmid DNA was purified from white colonies of Escherichia coli. The nucleotide sequence of the inserted DNA fragment was determined by a DNA sequencer. The entire nucleotide sequence is shown in SEQ ID NO: 2, and the entire amino acid sequence is shown in SEQ ID

NO: 1.

Example 2: Expression of protein in Escherichia coli

[0080] Primers corresponding to the N- and C-termini of the protein were produced from the obtained full-length nucleotide sequence. PCR was carried out using the primers and the first strand cDNA prepared in (2) above as a template. The used primers are as follows:

5'-CGGGATCCGACCATGGCTTCCAAAATCAGC-3' (primer 7) (SEQ ID NO: 9);

and

5'-CCGGAATTCTTAATTGTGACCAAGTTTAGATGGGCA-3' (primer 8) (SEQ ID NO: 10).

20

Composition of PCR reaction s	olution -
Template (first strand cDNA)	3 µ1
X 10 pyrobest buffer	5 μΙ
2.5 mM dNTPs	4 μΙ
100 μM primer 7	1 μί
100 μM primer 8	1 μΙ
Milli Q	35 µІ
Pyrobest polymerase (5 U/μ)	. 1μ -

30

RCR reaction conditions

94°C, 1 minute (PAD)

94°C, 30 seconds (denaturation)

55°C, 30 seconds (annealing of the primers to the template)

72°C, 1 minute (elongation of the primers)

[0081] 30 cycles consisting of the above 3 steps were carried out.

72°C, 7 minutes (final elongation)

Retention at 4°C

[0082] An amplified band of approximately 700 bp was cut out by agarose gel electrophoresis and then purified. The purified DNA fragment was subcloned into the BamHI-EcoRI site of a pRSET vector (Invitrogen); and it was then allowed to express in Escherichia coli (JM109-DE3). Since the expressed protein was constructed such that His-tag was attached to the N-terminus thereof, it was purified with Ni-Agarose gel (QIAGEN). Purification was carried out in accordance with the attached protocols.

Example 3: Analysis of protein

(1) Analysis of light-absorbing properties

[0083] The light-absorbing properties of the protein expressed in Example 2 were analyzed.

[0084] An absorption spectrum was measured using a 50 mM HEPES solution (pH 7.5) containing a 20 μ M chromoprotein. A molar absorption coefficient was calculated from the peak value of this spectrum. In the case of the chromoprotein derived from the green individual (referred to as KGr), the absorption peak was observed at 610 nm, and no fluorescence was detected (Table 1, Figure 1).

-55

Table 1

Properties of ch	romoprotein (KGr)				
Absorption maximum	Fluorescence maximum	Molar absorption coefficient	quantum yield	pH sensitivity	Number of amino acids
610 nm		66,700 (610 nm)	-	Non	232

(1) Measurement of pH sensitivity

The pH sensitivity of the protein expressed in Example 2 was analyzed.

The absorption spectrum of the protein was measured in the following 100 mM buffer solution (Figure 2) The following buffer solutions were used for each pH:

pH 4 and 5: Acetate buffer pH 6: MES buffer pH 7 and 8: HEPES buffer pH 9 and 10: Glycine buffer

The peak value did not significantly change at any pH

Example 4: Modification of KGr

[0085] In KGr, A at position 28 was substituted by G, E at position 41 was substituted by M, C at position 145 was substituted by S, and T at position 158 was substituted by I, so that the KGr was modified to have an absorption peak at 444 nm and to emit yellow fluorescence with a peak at 534 nm (Figure 3).

Example 5: Modification of properties of KGr by amino acid substitution

[0086] Y at position 64 that is a chromophore-forming amino acid (QYG) of KGr was substituted by L or M, so that the absorption peak became 418 nm and so that the absorption peak was shifted from the original absorption peak at 610 nm to the shorter wavelength side (Figures 1 and 2). The amino acid sequence of the protein wherein Y at position 64 was substituted by L is shown in SEQ ID NO: 11, and the nucleotide sequence thereof is shown in SEQ ID NO: 13, and the nucleotide sequence thereof is shown in SEQ ID NO: 13, and the nucleotide sequence thereof is shown in SEQ ID NO: 14.

[0087] E at position 41 was substituted by L, and F at position 80 was substituted by G, so that the absorption peak become 528 nm and so that the absorption peak was shifted from the original absorption peak at 610 nm to the shorter wavelength side (Figure 3). The amino acid sequence of this protein is shown in SEQ ID NO: 15, and the nucleotide sequence thereof is shown in SEQ ID NO: 16.

[0088] Y at position 64 that is a chromophore-forming amino acid (QYG) was substituted by F, so that the absorption peak became 412 nm, and so that the absorption peak was shifted from the original absorption peak at 610 nm to the shorter wavelength side and the protein was further modified to emit fluorescence with a peak at 504 nm (Figures 4 and 5). The amino acid sequence of this protein is shown in SEQ ID NO: 17, and the nucleotide sequence thereof is shown in SEQ ID NO: 18.

[0089] Y at position 64 that is a chromophore-forming amino acid (QYG) was substituted by H, so that the absorption peak became 418 nm, and so that the absorption peak was shifted from the original absorption peak at 610 nm to the shorter wavelength side and the protein was further modified to emit fluorescence with a peak at 520 nm (Figures 6 and 7). The amino acid sequence of this protein is shown in SEQ ID NO: 19, and the nucleotide sequence thereof is shown in SEQ ID NO: 20.

[0090] C at position 26 was substituted by V, C at position 143 was substituted by S, and P at position 199 was substituted by L, so that the absorption peak became 585 nm, and so that the absorption peak was shifted from the original absorption peak at 610 nm to the shorter wavelength side and the protein was further modified to emit fluorescence with a peak at 625 nm. This fluorescent protein was defined as KGr Rb (Figures 8 and 9). The amino acid sequence of this protein is shown in SEQ ID NO: 21, and the nucleotide sequence thereof is shown in SEQ ID NO: 22.

INDUSTRIAL APPLICABILITY

[0091] The present invention provides a novel chromoprotein derived from Cnidopus japonicus. The chromoprotein

of the present invention has desired fluorescence properties and low pH sensitivity. Thus, it is useful for molecular biology analysis.

:

15

20

30

35

40

45

50

55

	SEC	UENC	E LI	STIN	IG .			,	•						•	-
5	<11	0> R	RIKEN	I					••		٠.	•				
• • • • • • • • • • • • • • • • • • • •	<12	20> 0	hron	o pr	otei	n				•			. :			
	<13	A <0	3134	7A												
0	<16	i0> 2	2		•		-		•				•			
	· · · · · · · · · · · · · · · · · · ·	· .													· · .	
5	<21	0> 1	:								•	٠.				٠
	<21	1> 2	32										٠			. •
	<21	2> P	RT				*				٠					
o	<21	3> C	nido	pus	japo	nicu	s							. '		
	<40	0> 1		<i>:</i>	•	•	• .							. •	٠.	
5	Met	Ala	Ser	Lys	Ile	Ser	Asp	Asn	Val	Arg	Ile	Lys	Leu	Tyr	Met	Glu
	1				5				•	10					15	•
	Gly	Thr	Val	Asn	Asn	His	His	Phe	Met	Cys	G1u	Ala	Glu	Gly	Glu	Gly
0				20	٠.				25				٠.	30		
	Lys	Pro	Tyr	Glu	Gly	Thr	Gln	Met	Glu	Asn	lle	Lys	Val	Thr	Lys	Gly
5			35		.;			40					45			
	Gly	Pro	Leu	Pro	Phe	Ser	Phe	Asp	Ile	Leu	Thr	Pro	Asn	Cys	Gln	Tyr
 O		50					55					60		•	<*	
	Gly	Ser	Val	Ala	lle	Thr	Lys	Tyr	Thr	Ser	Gly	Ile	Pro	Asp	Tyr	Phe
	65					70					75					80
5	Lys	Gln	Ser	Phe	Pro	Glu	Gly	Phe	Thr	Trp	Glu	Arg	Thr	Thr	Ile	Tyr
		٠.		• • .	85			-		90					95	
)	Glu	Asp	Gly	Ala	Tyr	Leu	Thr	Thr	Ğln	Gln	Glu	Thr	Lys	Leu	Asp	Gly
		****		100					105					110		
: -	Asn	Cys	Leu	Val	Tyr	Asn	Ile	Lys	Ile	Leu	Gly	Cys	Asn	Phe	Pro	Pro
•			115		-			120	<i>:</i> . ·		• •		125			

	Asn	Gly	Pro	Val	Met	Gln	Lys	Lys	Thr	Gln	Gly	Trp	Glu	Pro	Cys	Cys	
5	•	130			٠.		135		••		• •	140					
	Glu	Met	Arg	Tyr	Thr	Arg	Asp	Gly	Yal	Leu	Cys	Gly	Gln	Thr	Leu	Met	
	145				•	150	,	•,			155		•			160	
10	Ala	Leu	Lys	Cys	Ala	Asp	Gly	Asņ	His	Leu	Ţħr	Cys	His	Leu	Arg	Thr	
				• •	165	٠.				170					175		
15	Thr	Tyr	Arg	Ser	Lys	Lys	Ala	Ala	Lys	Ala	Leu	Gln	Met	Pro	Pro	Phe	
				180				٠	185					190		·`.	
	His	Phe	Ser	Asp	His	Arg	Pro	Glu	Ile	Val	Lys	Val	Ser	Glu	Asn	Gly	
20	• • •		195		• , [†] •			200	•	,			205				•
	Thr	Leu	Phe	Glu	Gln	His	Glu	Ser	Ser	Val	Ala	Arg	Туг	Cys	Gln	Thr	
25		210	:				215	· · .				220	• .	<i>:</i>	·		
	Cys	Pro	Ser	Lys	Leu	Gly	His	Asn									
<i>30</i>	225					230						· · · .		•			
	₹ 91 ()> 2				•							· .	•			
35		;	aq .		· · · ·		·.		· .							`	÷
33		2> D1		.*													
	• .	٠.	٠.	s ous	iapoi	nicu	` : <u>,</u> S	٠.	. ,	٠.	· · ·		•				: .
40)>. 2	· · ·		٠.			· · · .			÷		•			• . •	
	atg	gct	tcc	aaa	atc	agc	gac	aat	gta	cgt	atc	aag	tta	tat	atg	gag	48
45	Met	Ala	Ser	Lys	Ile	Ser	Asp	Asn	Val	Arg	Ile	Lys	Leu	Tyr	Met	Glu	
	1		<i>:</i> .	••	5				. :	10			•		15		
50	ggc	aca	gtc	aac	aat	cat	cac	ttc	atg	tgc	gaa	gct	gaa	gga	gag	ggc	96
	Gly	Thr	Val	Asn	Asn	His	His	Phe	Met	Cys	Glu	Ala	Glu	Gly	Glu	Gly	
				20					25					30		· • .	٠
55	aag	cca	tac	gag	gga	act	caa	atg	gag	aac	ata	aaa	gtc	acc	aaa	gga	144
	٠.											:					

																•			
			Lys	Pro	Tyr	Glu	Gly	Thr	Gln	Met	Glu	Asn	Ile	Lys	Val	Thr	Lys	Gly	
5	•		٠.		35					40	•				45				
		,	ggc	cct	ctg	ccg	ttc	tct	ttt	gat	atc	ttg	acg	cct	aac	tgc	caa	tat	192
			Gly	Pro	Leu	Pro	Phe	Ser	Phe	Asp	Ile	Leu	Thr	Pro	Asn	Cys	Gln	Tyr	•
10		. •		50					55					60					
			gga	agc	gta	gcc	ata	acc	aag	tat	aca	tca	ggg	att	cca	gac	tac	ttt	240
15												Ser						•	
		·	65					70			•		75					80	-
		:	aag	caa	tct	ttt	cċt	gaa	gga	ttt	acc	tgg	gaa	aga	acc	aca	atc	tac	288
20				'	•			•				Trp			•			•	
	· ·			• .			85					.90			٠	• .	95	• • • • • • • • • • • • • • • • • • • •	
25		 	gaa	gat	ggg	gct	tac	ctt	aca	act	caa	caa	gaa	acc	aaa	ctt	gat	gga	336
			Glu	Asp	Gly	Ala	Tyr	Leu	Thr	Thr	Gln	Gln	Glu	Thr	Lys	Leu	Asp	Gly	٠
		٠		٠		100			٠		105	٠				110		٠.	٠
30	•		aat	tgc	ctc	gtc	tac	aat	att	aaa	atc	ctt	gga	tgt	aat	ttt	ccc	ccc	384
	: :					•						Leu							
35		1 41 1 .	·		115				• • •	120					125	,*		٠٠.	
			aat	ggt	cct	gtg	atg	cag	aag	aaa	acc	caa	ggc	tgg	gaa	ccc	tgt	tgc	432
			Asn	Gly	Pro	Val	Met	Gln	Lys	Lys	Thr	Gln	Gly	Trp	Glu	Pro	Cys	Cys	
40	4	,		130		:			135				,	140				•	
			gag	atg	cgc	tat	aca	cgt	gat	ggt	gtg	cta	tgt	ggc	caa	aca	tta	atg	480
45		•	Glu	Met	Arg	Tyr	Thr	Arg	Asp	Gly	Val	Leu	Cys	Gly	Gln	Thr	Leu	Met	
			145					150				-	155	٠.			=	160	
. •	•		gca	ctt	aaa	tgc	gcc	gat [.]	ggg	aac	cac	ctc	act	tgc	cat	ctg	aga	act	528
50		٠.	Ala	Leu	Lys	Cys	Ala	Asp	Gly	Asn	His	Leu	Thr	Cys	His	Leu	Arg	Thr	
				:			165		٠.			170					175	· ·	
55			act	tac	agġ	tcc	aaa	aag	gca	gca	aag	gcg	ttg	cag	atg	cca		ttc	576
							. •	•	•							٠		٠	

•	Thr Tyr Arg Ser Lys Lys Ala Ala Lys Ala Leu Gln Met Pro Pro Phe
.5	180 185 190
	cat tit toa gac cat cgt cct gaa ata gtg aag gtt toa gag aac ggc 624
	His Phe Ser Asp His Arg Pro Glu Ile Val Lys Val Ser Glu Asn Gly
10	195 200 205
	aca cta ttt gaa cag cac gaa agt tca gtg gcc agg tac tgt caa aca 672
15	Thr Leu Phe Glu Gln His Glu Ser Ser Val Ala Arg Tyr Cys Gln Thr
	210 215 220
20	Cys Pro Ser Lys Leu Gly His Asn
	225 230
<i>25</i>	223
	<210> 3
30	(211) 17
	<212> DNA
25	<213> Artificial Sequence
35	(220)
:	<223> Description of Artificial Sequence: Synthetic DNA
. 40	<400> 3
*	ggigsiccih tiscitt 17
45	⟨210⟩ 4
	<211> 44
50	(212) DNA
	<213> Artificial Sequence
	⟨220⟩
55	<pre><223> Description of Artificial Sequence: Synthetic DNA</pre>

	•		-
		<400> 4	
5		aactggaaga attcgcggcc gcagaatttt ttttttttt tttt	44
		⟨210⟩ 5	
10		⟨211⟩ 36	
. • •		(212> DNA	
15		<213> Artificial Sequence	
		⟨220⟩	
		(223) Description of Artificial Sequence: Synthetic	DN
20		<400> 5	
		ggccacgcgt cgactagtac gggiigggii gggiig 36	
25			
		⟨210⟩ 6	
		⟨211⟩ 22	
30		<212> DNA	
٠.		(213) Artificial Sequence	
35		⟨220⟩	
		(223) Description of Artificial Sequence: Synthetic	DN
40		⟨400⟩ 6	
40		agacgaggca atttccatca ag 22	
			•
45		<210> 7	
		⟨211⟩ 20	
50		<212> DNA	
		(213) Artificial Sequence	
	• • • • • •	<220>	

<223> Description of Artificial Sequence: Synthetic DNA

	<400> 7	
5	ggccacgcgt cgactagtac	20
	⟨210⟩ 8	
10	⟨211⟩ 24	
	<212> DNA	
15	<213> Artificial Sequence	
	⟨220⟩	
	<pre><223> Description of Artificial Sequence: Synth</pre>	etic DNA
20	⟨400⟩ 8	
	ggctacgctt ccatattggc agtt	24
25		•
	⟨210⟩ 9	
<i>30</i>	⟨211⟩ 30	
	<212> DNA	
	<213> Artificial Sequence	
35	⟨220⟩	• • •
	<223> Description of Artificial Sequence: Synth	etic DNA
40	<400> 9	
	cgggatccga ccatggcttc caaaatcagc	30
		•
,45	<210> 10	
	<211> 36	•
50	<212> DNA	• • • •
	<213> Artificial Sequence	
55	<220>	
	<223> Description of Artificial Sequence: Synthe	etic DNA

	<400.	> 10	,			•						·		•		
<i>5</i>	ccgga	aatt	ct	taat	tgtg	ac c	aagt	ttag	a tg	ggca			36			
,			•						. :				•			
	<210	11											•			
10	<2112	> 23	2.								•					
	<212	> PR	Ť				• • •									
15	<213	Cn	ido	ous .	japoı	nicu	s							:		
	<400	11	• '	٠.	٠.											•
	Met A	lla	Ser	Lys	Ile	Ser	Asp	Asn	Val	Arg	Ile	Lys	Leu	Tyr	Met	Glu
20	. 1				. 5	:				10			,	·. ·	15	
	Gly T	hr	Val	Asn	Asn	His	His	Phe	Met	Cys	Glu	Ala	Glu	Gly	Glu	Gly
25	•,			20					25				٠	- 30		٠
	Lys F	ro	Tyr	Glu	Gly	Thr	Gln	Met	Glu	Asn	Ile	Lys	Val	Thr	Lys	Gly
3 <i>0</i>			35	• •		٠.		40		,		٠.	45			
	Gly F	ro	Leu	Pro	Phe	Ser	Phe	Asp	Ile	Leu	Thr	Pro	Asn	Çys	Gln	Leu
		50	• :.			:	55	• .				60				
35	Gly S	er	Val	Ala	Ile	Thr	Lys	Tyr	Thr	Ser	Gly	Ile	Pro	Asp	Tyr	Phe
	65					70	٠		*,	<i>:</i>	75					80
10	Lys G	ln	Ser	Phe	Pro	Glu	Gly	Phe	Thr	Trp	Glu	Arg	Thr	Thr	Ile	Tyr
•			:		85				:	90					95	
	Glu A	sp	Gly	Ala	Tyr	Leu	Thr	Thr	Gln	G1n	Glu	Thr	Lys	Leu	Аsp	G1.y
15				100					105			·.		110		
	Asn C	ys	Leu	Val	Tyr	Asn	Ile	Lys	Ile	Leu	Gly	Cys	Aşn	Phe	Pro	Pro
5 <i>0</i>			115					120					125			٠
÷.,	Asn G	ly	Pro	Val	Met	Gln	Lys	Lys	Thr	Gln	Gly	Trp	Glu	Pro	Cys	Cys
	. 1	30				•	135					144				
.	Glu M	et .	Arg.	Tyr	Thr	Arg	Asp	Gly	.Val	Leu	Cys	Gly	Gln	Thr	Leu	Met

				-							•					
	145		•		-150					155	•				160	
5	Ala. Leu	Lys	Cys	Ala	Asp	Gly	Asn	His	Leu	Thr	Cys	His	Leu	Arg	Thr	
		•		165					170				-	175		
	Thr Tyr	Arg	Ser	Lys	Lys	Ala	Ala	Lys	Ala	Leu	Gln	Met	Pro	Pro	Phe	
10			180		-			185			•	•	190			
	His Phe	Ser	Asp	His	Arg	Pro	Glu	Ile	Val	Lvs	Val	Ser			Glv	
15		195		. •			200					205				
	Thr Leu		Glu	Gln	His	Glu		Ser	Val	Ala	Are			Gln	Thr	• :
	210					215					220	•,,	0,0	0111	:	• •
20	Cys Pro	Ser	Lvs	Leu	Gl v		Asn	¥ :.								
	225		-,-		230										•	
25		•	: .								:					
	<210> 1:	2					· :				•		· ·		•:	
	<211> 69	·. · ·	·	: 	• • •				· . ·		• •	•••				
<i>30</i>	<212> DI	•		,			· ·		•		:	·	* ** **			
	<213> C		us i	іарог	nicus	5	· .				. ; '	٠			•	:
35	<400> 1			, - ,		-						• • •			:::	
	atg gct		aaa	atc	agc	gac	aat	eta	 Cet	atc	225	tta	tat	atσ	gag	48
	Met Ala	• •	- "											• • •	,	
40	1		- ,	5					10					15	014	
	ggc aca	gtc	aac	aat	cat	cac	ttc-	atg		gaa	gct	gaa	gga	• ' . •	ggc.	96
45	Gly Thr	٠.	٠.				٠.						-	•		,
			20					25		• .		-	30		, u .	
	aag cca	tac		gga	act	caa	atg		aac	ata	ลลล	øtc		222	000	144
50	Lys Pro		·	•	•				•		٠.	•				•
	_,	35				-244	40				درب	45		uya	OLJ	•
55	ggc cct		CCa	tte	tct	: :::::		atr	 . † † a	200	cct		.+		c++	.102
	860 000		- СБ				Bar		· · · · · · · · · · · · · · · · · · ·	aug .		aac	rgç	Caa	CLL	174

	Gly	Pro	Leu	Pro	Phe	Ser	Phe	Asp	Ile	Leu	Thr	Pro	Asn	Cys	Gln	Leu	
5		50			•		55		٠.			60					
	gga	agc	gta	gcc	ata	acc	aag	tat	aca	tca	ggg	att	cca	gac	tač	ttt	240
	Gly	Ser	Val	Ala	Ile	Thr	Lys	Tyr	Thr	Ser	Gly	Ile	Pro	Asp	Tyr	Phe	
10	65					70					75		•			80	
	aag	caa	tct	ttt	cct	gaa	gga	ttt	acc	tgg	gaa	aga	acc	aca	atc	tac	288
15					Pro	•			•								. • •
					85					90		•			95		
	gaa	gat	ggg	gct	tac	ctt	aca	act	caa	caa	ssg	200	asa	ctt	gat	gga	336
20	Glu	Asp	Gly	Ala	Tyr	Leu	Thr	Thr	Gln	Gln	Glu	Thr	Lys	Leu	Asp	Gly	*. *.
	•		<i>i</i> .	100			÷		105	-1				110			
25	aat	tgc	ctc	gtc	tac	aat	att	aaa	atc	ctt	gga	tgt	aat	ttt	ccc	ccc	384
	Asn	Cys	Leu	Yal	Tyr	Asn	Ile	Lys	Ile	Leu	Gly	Cys	Asn	Phe	Pro	Pro	
		•	115					120					125	. *			· · · · ·
<i>30</i>	aat	ggt	cct	gtg	atg	cag	aag	aaa	acc	caa	ggc	tgg	gaa	ccc	tgt	tgc	432
	Asn	Gly	Pro	Yal	Met	Gln	Lys	Lys	Thr	Gln	Gly	Trp	Glu	Pro	Cys	Cys	
35		130					135				•	144			٠,		
	gag	atg	cgc	tat	aca	cgt	gat	ggt	gtg	ctà	tgt	ggc	caa	aca	tta	atg	480
40	Glu	Met	Arg	Tyr	Thr	Arg	Asp	Gly	Val	Leu	Cys	Gly	Gln	Thr	Leu	Met	
40	145			٠		150	•	•			155	•		. •		160	
	gca	ctt	aaa	tgc	gcc	gat	ggg	aac	cac	ctc	act	tgc	cat	ctg	aga	act	528
45	Ala	Leu	Lys	Cys	Ala	Asp	Gly	Ásn	His	Leu	Thr	Cys	His	Leu	Arg	Thr	
	•		٠		165	•		•		170	·			: :	175	•	*,
50	act	tac	agg	tcc	aaä.	aag	gca	gca	aag	gcg	ttg	cag	atg	cca.	ccc	ttc.	576
	Thr	Tyr	Arg	Ser	Lys	Lys	Ala	Ala	Lys	Ala	Leu	Gln	Met	Pro	Pro	Phe	
			•	180	•	٠	•		185					190			
55	cat	ttt	tca	gac	cat	cgt	cct	gaa	ata	gtg	aag	gtt	tca	gag	aac	ggc	624
		: .						•	•						•		

	His	Phe	Ser	·Asp	His	Arg	Pro	Glu	Ile	Val	Lys	.Val	Ser	Glu	Asn	Gly	-
* .	. :		195		•			200	••	•			205			. • •	.•
5	aca	cta	·ttt	gaa	cag	cac	gaa	agt	tca	gtg	gcc	agg	tac	tgt	caa	aca	67
	Thr	Leu	Phe	Glu	Gln	His	Glu	Ser	Ser	Val	Ala	Arg	Tyr	Cys	Gln	Thr	
10		210	٠.				215	•	 			220	٠				
· ·	tgc	cca	tct	aaa	ctt	ggt	cac	aat	taa					•	٠.		699
15	Cys	Pro	Ser	Lys	Leu	Gly	His	Asn									
	225	· • .				230			,		•		•				•
	· .	•		•							, ,						
20	⟨21	0> 1	3			-	٠		·	. :							
	<21	1> 2	32		٠.		•	· .					•				
25	⟨21	2> P	RT														•
	··<21	3> C	nido	pus .	japoi	nicu	s	•	-				- ···		•		
	<40	0> 1	3	•				: , ···	•					. • • •			
30	Met	Ala	Ser	Lys	Ile	Ser	Asp	Asn	Yal	Arg	Ile	Lys	Leu	Tyr	Met	Glu	
	. 1		: :a	÷ . · .	5	• . •				10					15		
35	Gly	Thr	Val	Asn	Asn	His	His	Phe	Met	Cys	Glu	Ala	Glu	Gly	Glu	Gly	
		· · · · ·		20				Ť	25					30			
40	Lys	Pro	Tyr	Glu	Gly	Thr	Gln	Met	Glu	Asn	Ile	Lys	Val	Thr	Lys	Gly	٠.
		-	35				•	40			· .		45		٠.		·.
	Gly	Pro	Leu	Pro	Phe	Ser	Phe	Asp	Ile	Leu	Thr	Pro	Asn	Cys	Gln	Met	
45		50				٠	55	·	٠.			6Ó			•		•
	Gly	Ser	Val	Ala	Ile	Thr	Lys	Tyr	Thr	Ser	Gly	Ile	Pro	Asp	Tyr	Phe	
50	65				-	70	į.				75			•	•	80	-
	Lys	Gln	Ser	Phe	Pro	Glu	Gly	Phe	Thr	Trp	Glu	Arg	Thr	Thr	Ile	Tyr.	
	. :				85					90		•	·		95		
55	Glu	Asp	Gly	Ala	Tyr	Leu	Thr	Thr	Gln	Gln	Glu	Thr	Lys	Leu	Asp	Gly	
						• •		:	•				٠.				٠.,

			· . · ·	100	•				105					110	•	٠	
	Asn	Cys	Leu.	Yal	Tyr	Asn	Ile	Lys	Île	Leu	Gly	Cys	Asn	Phe	Pro	Pro	
	•		115					120	•				125				
	Asn	Gly	Pro	Val	Met	Gln	Lys	Lys	Thr	Gln	Gly	Trp	Glu	Pro	Cys	Cys	
10		130					135	:				140					
	Glu	Met	Arg	Tyr	Thr	Arg	Asp	Gly	Val	Leu	Cys	Gly	Gln	Thr	Leu	Met	
15	145					150			**		155	•		. ,		160	
	Ala	Leu	Lys	Cys	Ala	Asp	Gly	Asn	His	Leu	Thr	Cys	His	Leu	Arg	Thr	
				•	165			•		170					175	·	
20	Thr	Tyr	Arg	Ser	Lys	Lys	Ala	Ala	Lys	Ala	Leu	Gln	Met	Pro	Pro	Phe	
		. •		180	:			٠	.185					190			
25	His	Phe	Ser	Asp	His	Arg	Pro	Glu	Ile	Val	Lys	Val	Ser	Glu	Asn	Gly	
		 	195			٠		200			•	٠,	205				
<i>30</i>	Thr	Leu	Phe	Glu	Gln	His	Glu	Ser	Ser	-Val	Ala	Arg	Tyr	Cys	Gln	Thr	
		210					215	•		•		220					• •
	Cys	Pro	Ser	Lys	Leu	Gly	His	Asn			•	٠٠.		÷			
35	225	. :		•	•	230		•••									
						•	•			:				•,			٠.
40	<210	i> 14	ł · .	•	· ·	•	. :							٠.	٠.,		. *
	<211			•		,			*		٠			-	•		
45	<212	•															
	<213			ous _	japor	nicus	5				- '	,.			•		
	<400	> 14	<u>.</u>		· .										:		
50	atg						•							•	•		48
	Met	Ala	Ser	Lys	Ile	Ser	Asp	Asn	Val	Arg	Ile	Lys	Leu	Tyr	Met	Glu	
55	·. 1	<i>•</i> .			5					10	. *				15		
	ggc	aca	gtc	aac	aat	cat	cac	ttc	atg	tgc	gaa	gct	gaa	gga	gag	ggc	96

		Gly	Thr	Val	Asn	Asn	His	His	Phe	Met	Cys	Glu	Ala	Glu	Gly	Glu.	Glý	
5					20					 25					30			
		aag	cca	tac	gag	gga	act	caa	atg	gag	aac	ata	aaa	gtc	acc	aaa	gga	144
10		Lys	Pro	Tyr	Glu	Gly	Thr	Gln	Met	Glu	Asn.	Ile	Lys	Val	Thr	Lys	Gly	
		**		35			٠		40		•			45			; -	
		ggc	cct	ctg	ccg	ttc	tçt	ttt	gat	atc	ttg	acg	cct	aac	tgc	caa	atg	192
15		Gly	Pro	Leu	Pro	Phe	Ser	Phe	Asp	Ile	Leu	Thr	Pro	Asn	Cys	Gln	Met	••••
			50	:		٠		55		•			60			•		٠.
20		gga	agc	gta	gcc	ata	acc	aag	tat	aca	tca	ggg	att	cca	gac	tac	ttt	240
		Gly	Ser	Val	Ala	Ile	Thr	Lys	Тут	Thr	Ser	Gly	Ile	Pro	Asp	Tyr	Phe	•
		65					70			;		75		٠. ،	•	` .	80	
25		aag	caa	tct	ttt	cct	gaa	gga	ttt	acc	tgg	gaa	aga	acc	aca	atc	tac	288
·.		Lys	Gln	Ser	Phe	Pro	Glu	Gly	Phe	Thr	Trp	Gļu	Arg	Thr	Thr	Ile	Tyr	
30	;				•	85		-			90				•	95		
		gaa	gat	ggg	gct	tac	ctt	aca	act	caa	caa	gaa	acc	aaa	ctt	gat	gga	336
35		Glu	Asp	Gly	Ala	Tyr	Leu	Thr	Thr	Gln	Gln	Glu	Thr	Lys	Leu	Asp	Gly.	
· •					100	·	:			105	٠.			•	110	٠	٠	
		7. 9		٠.					•						·	•		384.
40		Asn	Cys	Leu	Val	Tyr	Asn	Ile	Lys	Ile	Leu	Gly	Cys	Asn	Phe	Pro	Pro	
	•	· · ·	٠.	115					120					125			*	-
45	,		•	٠.														432
. :				Pro	Val	Met	Gln	Lys	Lys	Thr	Gln	Gly	Trp	Glu	Pro	Cys	Cys	
			130	٠.			:	135		· .			140					-
50		gag	atg	cgc	tat	aca	cgt	gat	ggt	gtg	cta	tgt	ggc	caa	aca	tta	atg	480
,		Glu	Met	Arg	Tyr	Thr	Arg	Asp	Gly	Val	Leu	Cys	Gly	Gln	Thr	Leu	Met	÷
55		145					.150	٠				155	٠.				160	•
		gca	ctt	aaa	tgc	gcc	gat	ggg	aac	cac	ctc	act	tgc	cat	ctg	aga	act	528

165 170	s His Leu Arg Thr
	175
act tac agg tcc aaa aag gca gca aag gcg ttg ca	g atg cca ccc ttc 576
Thr Tyr Arg Ser Lys Lys Ala Ala Lys Ala Leu Gl	n Met Pro Pro Phe
180 185	190
cat ttt tca gac cat cgt cct gaa ata gtg aag gt	t tca gag aac ggc 624
His Phe Ser Asp His Arg Pro Glu Ile Val Lys Va	l Ser Glu Asn Gly
195 200	205
aca cta ttt gaa cag cac gaa agt tca gtg gcc ag	g tac tgt caa aca 672
Thr Leu Phe Glu Gln His Glu Ser Ser Val Ala Ar	g Tyr Cys Gln Thr
210 215 22)
tgc cca tct aaa ctt ggt cac aat taa	699
Cys Pro Ser Lys Leu Gly His Asn	
225 230	
<210> 15	
35 〈211〉 232	
<212> PRT	
<213> Cnidopus japonicus	
<400> 15	
<pre>(400) 15 Met Ala Ser Lys Ile Ser Asp Asn Val Arg Ile Lys</pre>	s Leu Tyr Met Glu
	s Leu Tyr Met Glu 15
Met Ala Ser Lys Ile Ser Asp Asn Val Arg Ile Ly	15
Met Ala Ser Lys Ile Ser Asp Asn Val Arg Ile Lys 1 5 10	15
Met Ala Ser Lys Ile Ser Asp Asn Val Arg Ile Lys 1 5 10 Gly Thr Val Asn Asn His His Phe Met Cys Glu Ala 20 25	15 a Glu Gly Glu Gly 30
Met Ala Ser Lys Ile Ser Asp Asn Val Arg Ile Lys 1 5 10 Gly Thr Val Asn Asn His His Phe Met Cys Glu Als 20 25	15 a Glu Gly Glu Gly 30

• :	·		50				•	55				٠.	60				
		Gly	Ser	Val	Ala	Ile	Thr	Lys	Туг	Thr	Ser	Gly	Ile	Pro	Asp	Tyr	Gly
5		65					70		:		· · ·	75	÷				80
		Lys	Gln	Ser	Phe	Pro	Glu	Gly	Phe	Thr	Trp	Glu	Arg	Thr	Thr	Ile	Tyr
10	·					85				٠.	90	٠				95	
		Glu	Asp	Gly	Ala.	Tyr	Leu	Thr	Thr	Gln	Gln	Glu	Thr	Lys	Leu	Asp	Gly
15				•	100					105		•			110		
	· · · · · · · · · · · · · · · · · · ·	Asn	Cys	Leu	Val	Tyr	Asn	Ile	Lys	Ile	Leu	Gly	Cys	Asn	Phe	Pro	Pro.
				115		· · ·			120	· . : ·			· .	125			, .
20		Asn	Gly	Pro	Val	Met	Gln	Lys	Lys	Thr	Gln	Gly	Trp	Glu	Pro	Cys	Cys
			130				. ,	135	;			· · ·	140				
25		Glu	Met	Arg	Tyr	Thr	Arg	Asp	Gly	Val	Leu	Cys	Gly	Gln	Thr	Leu	Met
· ·.		145		. <i>:</i>	; · · .		150					155			٠.	÷.	160
30		Ala	Leu	Lys	Cys		Asp	Gly	Asn	His		Thr	Cys	His	Leu		
•						165			:		170					175	
		lhr	lyr	Arg		Lys	Lys	Ala	Ala	Lys	1	Leu	Gln	Met		Pro	Phe
35		นเล	Pho	20-	180	u: -	A	Dag	C1	185		1	V - 1		190		. 01 -
		111.2	1 116	195	vsh	1112	utg	110	200	Ile	Aai	Lys	491	205	Gin	ASN	GIA
40		Thr	Leu		Glu	Gln	His	Glu		Ser	Val	Ala	Ara	•	Cvs	Gln	The
	• . • •		210					215					220	.,_			
45		Cys	Pro	Ser	Lys	Leu											
	•	225					230				•		.,.	•	•	·	
50												;					
. ∵		<210)> 16	6				:		٠.							
		<21 1	l> 69	99			· .							•			
55		<212	2> DI	NA.			• .			` : :				· · · · · · · · · · · · · · · · · · ·		٠	
		٠															٠.

	<213> Cnid	opus japo	nicus		•			
5	<400> 16			· •:	·		•	
	atg gct tc	c aaa atc	agc gac	aat gta	cgt atc	aag tta	tat atg	ctg 48
·	Met Ala Se	r Lys Ile	Ser Asp	Asn Val	Arg Ile	Lys Leu	Tyr Met	Glu
10	1	5	· .		10		. 15	
· · .	ggc aca gt	c aac aat	cat cac	ttc atg	tgc gaa	gct gaa	gga gag	ggc 96
15	Gly Thr Va	l Asn Asn	His His	Phe Met	Cys Glu	Ala Glu	Gly Glu	Gly
. :		20		25	· · · · · · · · · · · · · · · · · · ·	•	30	
• • • • • • • • • • • • • • • • • • • •	aag cca ta	c gag gga	act caa	atg ctt	aac ata	aaa gtc	acc aaa	gga 144
20	Lys Pro Ty	r Glu Gly	Thr Gln	Met Leu	Asn Ile	Lys Val	Thr Lys	Gly
	39	5		40		45		
25	ggc cct ct	g ccg ttc	tct ttt	gat atc	ttg acg	cct aac	tgc caa	tat 192
	Gly Pro Le	u Pro Phe	Ser Phe	Asp Ile	Leu Thr	Pro Asn	Cys Gln	Met
<i>30</i>	50	; ·	55			60		
	gga agc gta	a gcc ata	acc aag	tat aca	tca ggg	att cca	gac tac	ggt 240
	Gly Ser Va	l Ala Ile	Thr Lys	Tyr Thr	Ser Gly	Ile Pro	Asp Tyr	Gly
35	65	· · ·	70		75			80
	aag caa tc	t ttt cct	gaa gga	ttt acc	tgg gaa	aga acc	aca atc	tac 288
40	Lys Gln Ser	r Phe Pro	Glu Gly	Phe Thr	Trp Glu	Arg Thr	Thr Ile	Tyr
		85			90	,	95	
	gaa gat ggg	g gct tac	ctt aca	act caa	caa gaa	acc aaa	ctt gat	gga 336
45	Glu Asp Gly	y Ala Tyr	Leu Thr	Thr Gln	Gln Glu	Thr Lys	Leu Asp	Gly
		100		105		· · · .	110	
50	aat tgc cto	gtc tac	aat att	aaa atc	ctt gga	tgt aat	ttt ccc	ccc 384
	Asn Cys Leu	ı Val Tyr	Asn Ile	Lys Ile	Leu Gly	Cys Asn	Phe Pro	Pro
	118	5		120		125		. :
55	aat ggt cct	t gtg atg	cag aag	aaa acc	caa ggc	tgg gaa	ccc tgt	tgc 432
	•							

	Asn	Gly	Pro	Val	Met	Gln	Lys	Lys	Thr	Gln	Gly	Trp	Glu	Pro	Cys	Cys	
.		130				•	135		٠.			140					
	gag	atg	cgc	tat	aca	cgt	gat	ggt	gtg	cta	tgt	ggc	caa	: aca	tta	atg	480
	Glu	Met	Arg	Tyr	Thr	Arg	Asp	Gly	Val	Leu	Cys	Gly	Gln	Thr	Leu	Met	
10	145		•			150					155				١.	160	,
•	gca	ctt	aaa	tgc	gcc	gat	ggg	aac	cac	ctc	act	tgc	cat	ctg	aga	act	528
15	Ala	Leu	Lys	Cys	Ala	Asp	Gly	Asn	His	Leu	Thr	Cys	His	Leu	Arg	Thr	
					165	٠.			. `	170	•				175		
	act	tac	agg	tcc	aaa	aag	gca	gca	aag	gcg	ttg	cag	atg	cca	ccc	ttc	576
20	Thr	Tyr	Àrg	Ser	Lys	Lys	Ala	Ala	Lys	Ala	Leu	Gln	Me.t	Pro	Pro	Phe	
				180	•		· ·	 	185					190			
25	cat	ttt	tca	gac	cat	cgt	cct	gaa	ata	gtg	aag	gtt	tca	gag	aac	ggc	624
	His	Phe	Ser	Asp	His	Arg	Pro	Glu	Ile	Val	Lys	Val	Ser	Glu	Åsn	Gly	· · . . :
			195	•.	•.			200			`		205				. •
30	aca	cta	ttt	gaa	cag	cac	gaa	agt	tca	gtg	gcc	agg	tac	tgt	caa	aca	672
	Thr	Leu	Phe	Glu	Gln	His	Glu	Ser	Ser	Val	Ala	Arg	Tyr	Cys	Gln	Thr	
35		210	٠		· · · · ·		215	•		•	• • •	220	,		• ,		
	tgc	cca	tct	aaa	ctt	ggt	cac	aat	taa				•	٠,			699
40	Cys	Pro	Ser	Lys	Leu	Gly	His	Asn	· · ·			:					
	225			·		230						•					
						· :			•			:		:	,.		
45	<210)> 17	7					•				:	٠.	•			
	<21	> 2	32			: : :					•					-	•
50 "	<212	2> PI	RT	· .	, •		•				•					· .	
	<213	3> Cı	ni dop	ous	japor	nicus	S	•			·. ·	•					•
	<40 ()> 17	7	•			•	•	٠.		•						
55	Met	Ala	Ser	Lys	Ile.	Ser	Asp	Asn	Val	Arg.	Ile	Lys	Leu	Tyr	Met	Glu	• • •

				:		5				-	10					15	
5		Gly	Thr	Val	Asn	Asn	His	His	Phe	Met	Cys	Glu	Ala	Glu	Gly	Glu	G1
			,		20	•		•		25	•				30		
	:	Lys	Pro	Tyr	Glu	Gly	Thr	Gln	Met	Glu	Asn	Île	Lys	Val	Thr	Lys	G1
				35		•			40					45			
		Gly	Pro	Leu	Pro	Phe	Ser	Phe	Asp	Ile	Leu	Thr	Pro	Asn	Cys	Gln	Ph
15			- 50	•	٠			55					60		•	·	
		Gly	Ser	Val	Ala	Ile	Thr	Lys	Tyr	Thr	Ser	Gly	Ile	Pro	Asp	Tyr	Ρħ
20		65			· · .		70				•	75					8
:U		Lys	Gln	Ser	Phe	Pro	Glu	Gly	Phe	Thr	Trp	Glu	Arg	Thr	Thr	Ile	Тy
		•				85					90				٠.	95	-
25		Glu	Asp	Gly	Ala	Tyr	Leu	Thr	Thr	Gln	Gln	Glu	Thr	Lys	Leu	Asp	G1
	· · · · ·			·. ' :	100					105		÷			110		
30		Asn	Cys	Leu	Yal	Tyr	Asn	Ile	Lys	Ile	Leu	Gly	Cys	Asn	Phe	Pro	Pro
			·	115	:			· .	120		٠.			125			
• .		Asn	Gly	Pro	Val	Met	Gln	Lys	Lys	Thr	Gln	Gly	Trp	Glu	Pro	Cys	Cys
15			130		·. :			135				٠.	140				•
		Glu	Met	Arg	Tyr	Thr	Arg	Asp	Gly	Val	Leu	Cys	Gly	Gln	Thr	Leu	Met
ю .	•••	145			• :	•.	150			•		155		• 1	٠.	-	160
		Ala	Leu	Lys	Cys	Ala	Asp	Gly	Asn	His	Leu	Thr	Cys	His	Leu	Arg	Thi
			. •	•		165					170					175	
	• •	Thr	Tyr	Arg	Ser	Lys	Lys	Ala	Ála	Lys	Ala	Leu	Gln	Met	Pro	Pro	Phe
		·			180					185			:		190		
Ю. [:]		His	Phe	Ser	Asp	His	Arg	Pro	Glu	Ile	Val	Lys	Val	Ser	Glu	Asn	Gly
	÷			195	•		•		200		٠.		٠	205		,	: -
5		Thr	Leu	Phe	Glu	Gln	His	G1u	Ser	Ser	Val	Aļa	Arg	Tyr	Cys	Gln	Thr
٠.			210		•	· ·	• :	215			•		220				

	Cys	Pro	Ser	Lys	Leu	Gly	His	Asn									
5	225				•	230		· :	٠.						•		
					, .									•			
: :	<210)) 	8			:		· · · ,									
10	<21	1> 69	99					÷	*	•							٠.
	<212	2> DI	NA								•						
15	<21	3> Cı	nidoj	pus ,	japoi	nicu	s										
	<400)> 18	8						*			• :					• •
	atg	gct	tcc	aaa	atc	agc	gac	aat	gta	cgt	atc	aag	tta	tat	atg	gag	48
20	Met	Ala	Ser	Lys	lle	Ser	Asp	Asn	Val	Arg	Ile	Lys	Leu	Tyr	Met	Glu	
		· ·	٠	<i></i>	5			٠.	•	-10		. ,			15		
25	ggc	aca	gtc	aac	aat	cat	cac	ttc	atg	tgc	gaa	gct	gaa	gga	gag	ggc	96
	Gly	Thr	Val	Asn	Asn	His	His	Phe	Met	Cys	Glu	Ala	Glu	Gly	Glu	Gly	
<i>30</i>	.÷			20			•		25			•		30			· :. ,
	aag	cca	tac	gag	gga	act	caa	atg	gag	aac	ata	aaa	gtc	acc	aaa	gga	144
	Lys	Pro	Tyr	Glu	Ģly	Thr	Gln.	Met	Glu	Asn	He	Lys	Val	Thr	Lys	Gly	
3 5	· · · :	٠	35			١.	: :	40					45	٠			
	ggc	cct	ctg	ccg	ttc	tct	ttt	gat	atc	ttg	acg	cct	aac	tgc	caa	ttt	192
40	Gly	Pro	Leu	Pro	.Phe.	Ser	Phe	.Asp	Ile	Leu	Thr	Pro	Asn	Cys	Gln	Phe	
. ,		50					55	· .				60	٠		· · .	٠.	• • •
	gga	agc	gta	gcc	ata	acc	aag	tat	aca	tca	ggg	att	cca	gac	tac	ttt	240
45	Gly	Ser	Val	Ala	Ile			Tyr	Thr	Ser	Gly	Ile	Pro	Asp	Tyr	Phe	
	65					70			!		75			• :		80	
50					cct												288
	Lys	Gln	Ser	Phe	Pro	Glu	Gly	Phe	Thr	Trp	Glu	Aŗg	Thr	Thr	Ile	Tyr	
		;			85				•	90				•	95		
55	gaa	gat	ggg	gct	tac	ctt	aca	act	caa	caa	gaa	acc	aaa	ctt	gat	gga	336
	٠.						•										

	Glu	Asp	Gly	Ala	Tyr	Leu	Thr	Thr	Gln	Gln	Glu	Thr	Lys	Leu	Asp	Gly	
5			•.	100					105			•		110			
	aat	tgc	ctc	gtc	tac	aat	att	aaa	atc	ctt	gga	tgt	aat	ttt	ccc	ссс	384
	Asn	Cys	Leu	Val	Tyr	Asn	Ile	Lys	Ile	Leu	Gly	Cys	Asn	Phe	Pro	Pro	
			115			_		120					125			٠	
	aat	ggt	cct	gtg	atg	cag	aag	aaa	acc	caa	ggc _.	tgg	gaa	ccc	tgt	tgc	432
15	Asn	Gly	Pro	Val	Met	Gln	Lys	Lys	Thr	Gln	Gly	Trp	Glu	Pro	Cys	Cys	
		130	• .			•	135		٠		. '	140					
20	gag	atg	cgc	tat	aca	cgt	gat	ggt	gtg	cta	tgt	ggc	caa	aca	tta	atg	480
	Glu	Met	Arg	Tyr	Thr	Arg	Asp	Gly	Val	Leu	Cys	Gly	Gln	Thr	Leu	Met	• •
25	145					150					155	•				160	
	gca	ctt	aaa	tgc	gcc	gat	ggg	āac	cac	ctc	act	tgc	cat	ctg	aga	act	528
	Ala	Leu	Lys	Cys	Ala	Asp	Gly	Asn	His	Leu	Thr	Cys	His	Leu	Arg	Thr	•
30				•	165.		• • • •			170	· .				175		•
****	act	tac	agg	tcc	aaa	aag	gca	gca	aag	gcg	ttg	cag	atg	сса	ccc	ttc	576
35	Thr	Tyr	Arg	Ser	Lys	Lys	Ala	.Ala	Lys	Ala	Leu	Gln	Met	Pro	Pro	Phe	
				180					185					190			
40	cat	ttt	tca	gac	cat	cgt	cct	gaa	ata	gtg	aag	gtt	tca	gag	aac	ggc	624
	His	Phe	Ser	Asp	His	Arg	Pro	Glu	Ile	Val	Lys	Val	Ser	Glu	Åsn	Gly	
		•	195	:				200					205				
45 -	aca	cta	ttt	gaa	cag	cac	gaa	agt	tca	gtg	gcc	agg	tac	tgt	caa	aca	672
	Thr	Leu	Phe	Glu	Gln	His	Glu	Ser	Ser	Val	Ala	Arg	Tyr	Cys	Gln	Thr	
50		210					215					220		• .			
	tgc	cca	tct	aaa	.ctt	ggt	cac	aat	taa		•		•	•••			699
<i>E E E E E E E E E E</i>	Cys	Pro	Ser	Lys	Leu	Gly	His	Asn	-		٠						
55	225				·	230	•										

	-	<210)> 19	9 .						٠							
		<21 .	1> 23	32			-			•• •	,		•				٠.
		<21 2	2> PI	RT				,					•		•		
٠.	· · · · · · · · · · · · · · · · · · ·	(21	3> Cr	ni doj	pus .	japor	nicus	s	• :		-		٠	٠.	. :		:
0		<400)> 19	Э													
		Met	Ala	Ser	Lys	Ile	Ser	Asp	Asn	Val	Arg	Ile	Lys	Leu	Tyr	Met	Glu
5 .		. 1			٠	5			.•		10			,		15	
4		Gly	Thr	Val	Asn	Asn	His	His	Phe	Met	Cys	Glu	Ala	Glu	Gly	Glu	Gly
			•		20		•			25					30		
0		Lys	Pro	Tyr	Glu	Gly	Thr	G1n	Met	Glu	Asn	Ile	Lys	Val	Thr	Lys	Gly
:			٠.	35		.· *		•	40				٠	45			
5		Gly	Pro	Leu	Pro	Phe	Ser	Phe	Asp	Ile	Leu	Thr	Pro	Asn	Cys	Gln	His
			50					55	• • •	•			60		1 11		•
'n		Gly	Ser	Val	Ala	Ile	Thr	Lys	Tyr	Thr	Ser	Gly	Ile	Pro	Asp	Tyr	Phe
,	·	65			•		. 70					75		• • •			80
		Lys	Gln	Ser	Phe	Pro	Glu	Gly	Phe	Thr	Trp	Glu	Arg	Thr	Thr	Ile	Tyr
5						85					90					95	
•		Glu	Asp	Gly	Ala	Tyr	Leu	Thr	Thr	Gln	Gln	Glu	Thr	Lys	Leu	Asp	Gly
O			 	•	100		•	* *	•	105			• .	:	110	· ;; · ;; .	
		Asn	Cys	Leu	Val	Tyr	Asn	Ile	Lys	Ile	Leu	Gly	Cys	Asn	Phe	Pro	Pro
			:	. 115		٠			120				•	125	٠.		· · ·
15	•	Asn	Gly	Pro	Val	Me.t	Gln	Lys	Lys	Thr	Gln	Gly	Trp	Glu	Pro	Cys	Cys
: .		· ·	130					135					140				
0		Glu	Met	Arg	Tyr	Thr	Arg	Asp	Gly	Val	Leu	Cys	Gly	Gln	Thr	Leu	Met
		145				:	150			·		155					160
		Ala	Leu	Lys	Cys	Ala	Asp	Gly	Äsn	His	Leu	Thr	Cys	His	Leu	Arg	Thr
~• . ·		•	·.			165	·	• -	_		170	٠.		• • •		175	

	Thi	r Tyr	Arg	Ser	Lys	Lys	Ala	Ala	Lys	Ala	Leu	Gln	Met	Pro	Pro	Phe	
5	· .			180					185					190	·,		
•	His	s Phe	Ser	Asp	His	Arg	Pro	Glu	Ile	Val	Lys	Val	Ser	Glu	Asn	Gly	
. · · ·		-	195	•				200					205				
ro , .	Thi	r Leu	Phe	Gļu	Gln	His	Glu	Ser	Ser	Val	Ala	Arg	Tyr	Cys	Gln	Thr	
	:	210					215			٠.		220					٠
15	Cys	s Pro	Ser	Lys	Leu	Gly	His	Asn			:	•					
	225	5		-		230						٠, ٠					
											•	•					
20	<2]	10> 2	0.		•	. *			• .					٠.	•		٠.
		11> 6	٠.				• .										
25		12> Di		1.	•						*			٠.		-	•
·		13> C		ous .	iapo	nicus	s S	٠			•			· · .			
		00> 2	•		3 - 2 ,		-					•		· · · · · ·			
30	•	g gct		aaa	atc	agc	gac	aat	ota	cot	atc	220	tta	tat	ato	asa	48
		t Ala			:		;			•••					٠,	-	
35	1	, <u>.</u>			5		ш			10			Deu	: ,	15	U1u	: -
•	gar	c aca	øtc	aac		cat	cac	Ttr	atσ			get	633			aac	96
	•	, Thr							•				•		٠.		
ю.	. 01)	1111	141	20					25	O) S	GIU	VIO	ijι		Olu	GIA	•
	220		tac		aas	`act	css	ata		224			-+-	30			144
15	• •	g cca s Pro						•			*.			-			144
	Lys	, 110			Uly		UIII		Olu	ASII	ije	LYS		inr	LYS	GIY	
. :			35			4.1		40					45				100
50 ·		cct			•								•			· .	192
· .·	Gly	/ Pro	Leu	Pro	rne	261		Asp	He	Leu	Thr		Asn	. Cys :	Gļn	His	
 55		50		•			- 55					. 60	-				·
	gga	a agc	gta	gcc	ata	acc	aag	tat	aca	tca	ggg	att	cca	gac	tac	ttt	240

-	٠.	Gly	Ser	Val	Ala	Ile	Thr	Lys	Tyr	Thr	Ser	Gly	Ile	Pro	Asp	Tyr	Phe	!
. 5		65	:				70		• • •	٠.		75					80	
		aag	caa	tct	ttt	cct	gaa	gga	ttt	acc	tgg	gaa	aga	acc	aca	atc	tac	288
	• .	Lys	Gln	Ser	Phe	Pro	G1 _u	Gly	Phe	Thr	Trp	Glu	Arg	Thr	Thr	Ile	Tyr	
10				·.		85					90		,			95		
		gaa	gat	ggg	gct	tac	ctt	aca	act	caa	caa	gaa	acc	aaa	ctt	gat	gga	336
-15		Glu	Asp	Gly	Ala	Tyr	Leu	Thr	Thr	Gln	Gln	Glu	Thr	Lys	Leu	Asp	Gly	
	: .				100				•	105				•	110			-
20		aat	tgc	ctc	gtc	tac	aat	att	aaa	atc	ctt	gga	tgt	aat	ttt	ccc	ccc	384
		Asn	Cys	Leu	Val	Tyr	Asn	Ile	Lys	Île	Leu	Gly	Cys	Asn	Phe	Pro	Pro	-
				115			•		120					125		·		•
25	• .		· · · · ·		gtg													432
•		Asn		Pro	Val	Met	Gln	Lys	Lys	Thr	Gln	Gly	Trp	Glu	Pro	Cys	Cys	
<i>30</i>			130	· ·	٠.	: 	٠.	135		-	· ·:		140			•		
			5-		tat									•				480
05			Met	Arg	Tyr		_	Asp	Gly	Val	Leu	Cys	Gly	Gln	Thr	Leu	Met	
35	• 1 * .	145					150				• •	155		٠.,			160	٠.
	• • • •	• •			tgc													528
40		YIS	Leu	Lys	Cys		Asp	Gly	Asn	His	٠.	Thr	Cys	His	Leu	٠.	Thr	
. • ;						.65		•	٠		170					175		
45	·. ·.				tcc													
	. :	inr	lyr	Arg	Ser	Lys	Lys	Ala			Ala	Leu	Gln			Pro	Phe	
				***	180		·	:		185		٠			190			
50		.:			gac										• •			624
	٠	піѕ	rne		Asp	nıs	Arg	Pro		lle	Val	Lys	Val	•	Glu	Asn	Gly	
55		·.	. 4	195	:	• • • • • • • • • • • • • • • • • • • •			200			•		205	•			
*		aca	cta _.	III	gaa	cag	cac	gaa	agt	tca	gtg	gcc	agg	tac	tgt	caa	aca	672

FP 1 512 744 Δ

	•	T	r	Leu	Phe	Glu	Gln	His	Glu	Ser	Ser	Val	Ala	Arg	Tyr	Cys	Gln	Thr	
5				210					215		••	: •	•	220	•				
		· iti	c (ca	tct	aaa	ctt	ggt	cac	aat	taa								699
	•	C	s I	ro	Ser	Lys	Leu	Gly	His	Asn							,		
10	٠.	22	5				•	230		-							•		
	•		٠,															:	
15		· <2	10	2	ĺ						;					٠	•		
	• •	Ċ2	11)	2:	32	,	. " ,	:			·						•	•	
		· <2	12	P	RT		:									••			
20		<2	13	Cı	ni doj	pus	japoi	nicu	s			r				٠.			
	. :	<4	00)	2	1			:			•		÷.				· .		
25		Me	t /	lla	Ser	Lys	Ile	Ser	Asp	Asn	Val	Arg	Ile	Lys	Leu	Tyr	Met	Glu	
			1	٠.	• .•	٠	5	٠				10					15		• .
<i>30</i>		.G3	y : 1	hr	Val	Asn	Asn	His	His	Phe	Met	Val	Glu	Ala	Glu	Gly	Glu	Gly	
	₹.				.:	20				. •	25					30	÷ .		
		L	s F	ro	Туг	Glu	Gly	Thr	Gln	Met	Glu	Asn	Ile	Lys	Val	Thr	Lys	Gly	
35	•			. :	35		.: <i>!</i>	:		40					45	•	:		
		G1	y I	ro	Leu	Pro	Phe	Ser	Phe	Asp	Ile	Leu	Thr	Pro	Asn	Cys	Gln	Met	
40			· .	50			·		55		•			60	• :			•	
. :		G1	y S	er	Yal	Ala	Ile	Thr	Lys	Tyr	Thr	Ser	Gly	Ile	Pro	Asp	Tyr	Phe	
		ε	5	٠,		٠		. 70					75					80	
45	•	Ly	s (ln	Ser	Phe	Pro	Glu	Gly	Phe	Thr	Trp	Glu	Arg	Thr	Thr	Ile	Tyr	
							85					90			•	÷	95	•	•
	٠.					•		-											
50	٠.	G1	u A	sp	Gly	Ala		Leu	Thr	Thr	Gľn	Gln	Glu	Thr	Lys	Leu	Asp	Gly	-
50		G]	u A	sp	Gly	Ala 100		Leu	Thr	Thr	GI'n 105	Gln	Glu	Thr	Lys	Leu 110	Asp	Gly	
<i>50</i>	:				•	100	Tyr				105	:	٠			110	Asp Pro	 	

	Asn Gly Pi	ro Val	Net	Gln	Lys	Lys	Thr	Gln	Gly	Trp	Glu	Pro	Ser	Cys	
<i>5</i>	130				135		٠.			140.				•	•
	Glu Met Ar	g Tyr	Thr	Arg	Asp	Gly	Val	Leu	Cys	Gly	Glń	Thr	Leu	Met	•
	145			150					155					160	•
10	Ala Leu Ly	ıs Cys	Ala	Asp	Gly	Asn	His	Leu	Thr	Cys	His	Leu	Arg.	Thr	
			165					170			•		175		
15	Thr Tyr Ar	g Ser	Lys	Lys	Ala	Ala	Lys	Ala	Leu	Gln	Met	Pro	Pro	Phe	÷
	·	180					185					190	**		· . ·
	His Phe Se	er Asp	His	Arg	Leu	Glu	lle	Val	Lys	Val	Ser	Glu	Asn	Gly	
20	19	95				200		•			205		,	•	
	Thr Leu Pl	ne Glu	Gln	His	Glu	Ser	Ser	Val	Ala	Arg	Tyr	Cys	Gln	Thr	
25	210				215					220		٠.			
	Cys Pro Se	er Lys	Leu	Gly	His	Asn			÷. † .	• • •	<i>:</i>		٠.		٠.
<i>30</i>	225			230					٠.	•					
					•		٠	•		. •		•			
	<210> 22								· .						
35	<211> 699			•	:: :								•		-
	<212> DNA	•				. ,					·				
40	<213> Cnic	lopus (Japoi	nicus	5							•	• • •	٠	
	<400> 22	:							-4-			٠.			40
40	atg gct to		٠.					٠.		. :.					48
45	Met Ala Se	er Lys	. 5	261	NSD	NSII	vai	Arg	ire	Lys	Leu	ıyr 		GIU	
				cat	626	++0	o.t.a			+			15	:	06
50	ggc aca gt	:					•							·	96
	Gly Thr Va	-	ASII	nIS	urz	rne		vai	otn	ита	GIU	٠	GIU	GIY	
55	222 222 +-	20	866	act		a+-	25				· .	30			1.44
-	aag cca ta	ic Rak	RRQ	act	Lad	alg.	Rag	aac	ala	856	gtc	acc	aaa	gga	144

	Lys	Pro	Tyr	Glu	Gly	Thr	Gln	Met	Glu	Asn	Ile	Lys	Val	Thr	Lys	Gly	
5		٠	35		•			40	••		.•	•	45				
	ggc	cct	ctg	ccg	ttc	tct	ttt	gat	atc	ttg	acg	cct	aac	tgc	caa	tat	192
	Gly	Pro	Leu	Pro	Phe	Ser	Phe	Asp	Ile	Leu	Thr	Pro	Asn	Cys	Gln	Met	
10		50	•		•		55		•	·		60			. ,		
	gga	agc	gta	gcc	ata	acc	aag	tat	aca	tca	ggg	att	cca	gac	tac	ttt	240
15	Gly	Ser	Val	Ala	Ile	Thr	Lys	Tyr	Thr	Ser	Gly	Ile	Pro	Asp	Tyr	Phe	: .
,	65	:		٠.		70	· . · .				75		*			80	
20	aag	caa	tct	ttt	cct	gza	gga	ttt	300	tgg	gaa	aga	acc	aca	atc	tac	288
20	Lys	Gln	Ser	Phe	Pro	Glu	Gly	Phe	Thr	Trp	Glu	Arg	Thr	Thr	Ile	Tyr	٠
	er Ger		÷	٠ .	85	**	,			90					95	. ′	
25	gaa	gat	ggg	gct	tac	ctt	aca	act	caa	caa	gaa	acc	aaa	ctt	gat	gga	336
	Glu	Asp	Gly	Ala	Tyr	Leu	Thr	Thr	Gln	Gln	Glu	Thr	Lys	Leu	Asp	Gly	
<i>30</i>		:		100					105	., .			٠,٠	110	: .	:	
				gtc	٠.											•	
	Asn	Cys	Leu	Val	Tyr	Asn	Ile	Lys	Ile	Leu	Gly	Cys	Asn	Phe	Pro	Pro	
35			115	·. ·				120	٠.				125				
		٠ -		gtg								•		• •			432
40			Pro	Val	Met	Gln	•	Lys	Thr	Gln	Gly		Glu	Pro	Ser	Cys	-
		130				٠	135				•	140		·			
4-		,		tat	٠.			•	-	• • •	•	-				•	480
45		Met	Arg	Tyr	inr		Asp	GIA	Val	Leu		Gly.	Gln	Thr	Leu		
	145					150					155					160	500
50	•		•	tgc			•						:	٠.		· •	528
. · ·	Ala	ren	LYS	cys		ASP	GIA	ASN	HIS		ihr	Cys	His	.Leu	•	lhr	•
55					165					170			,•		175		
-	act	tac	agg	tcc	aaa	aag	gca	gca	aag	gcg	ttg	cag	atg	cca	ccc	ttc	576

Thr Tyr Arg Ser Lys Lys Ala Ala Lys Ala Leu Gln Met Pro Pro Phe 180 185 190 cat ttt tca gac cat cgt ctt gaa ata gtg aag gtt tca gag aac ggc 624 His Phe Ser Asp His Arg Leu Glu Ile Val Lys Val Ser Glu Asn Gly 195 200 205 aca cta ttt gaa cag cac gaa agt tca gtg gcc agg tac tgt caa aca 672 Thr Leu Phe Glu Gln His Glu Ser Ser Val Ala Arg Tyr Cys Gln Thr 210 215 tgc cca tct aaa ctt ggt cac aat taa 699 Cys Pro Ser Lys Leu Gly His Asn

Claims

- 1. A chromoprotein derived from Cnidopus japonicus having the following properties:
 - (1) the absorption maximum wavelength is 610 nm, and fluorescence is not emitted:
 - (2) the molar absorption coefficient is 66,700 at 610 nm; and
 - (3) the pH sensitivity of light-absorbing property is stable at between pH 4 and pH 10.
 - 2. A chromoprotein having either one of the following amino acid sequences:
 - (a) the amino acid sequence shown in SEQ ID NO: 1; and
 - (b) an amino acid sequence comprising a deletion, substitution and/or addition of one or several amino acids with respect to the amino acid sequence shown in SEQ ID NO: 1, and having light-absorbing properties.
 - 3. A chromoprotein capable of emitting fluorescence, which has an amino acid sequence, wherein, with respect to the amino acid sequence shown in SEQ ID NO: 1, alanine as an amino acid residue at position 28 is substituted by glycine, glutamic acid as an amino acid residue at position 41 is substituted by methionine, cysteine as an amino acid residue at position 145 is substituted by serine, and threonine as an amino acid residue at position 158 is substituted by isoleucine.
 - 4. A chromoprotein having an amino acid sequence wherein tyrosine as an amino acid residue at position 64 is substituted by leucine with respect to the amino acid sequence shown in SEQ ID NO: 1.
 - A chromoprotein having an amino acid sequence wherein tyrosine as an amino acid residue at position 64 is substituted by methionine with respect to the amino acid sequence shown in SEQ ID NO: 1.
 - 6. A chromoprotein having an amino acid sequence, wherein glutamic acid as an amino acid residue at position 41 is substituted by leucine, and phenylalanine as an amino acid residue at position 80 is substituted by glycine, with respect to the amino acid sequence shown in SEQ ID NO: 1.
 - 7. A chromoprotein capable of emitting fluorescence, which has an amino acid sequence wherein tyrosine as an

amino acid residue at position 64 is substituted by phenylalanine with respect to the amino acid sequence shown in SEQ ID NO: 1.

- 8. A chromoprotein capable of emitting fluorescence, which has an amino acid sequence wherein tyrosine as an amino acid residue at position 64 is substituted by histidine with respect to the amino acid sequence shown in SEQ ID NO: 1.
 - 9. A chromoprotein capable of emitting fluorescence, which has an amino acid sequence, wherein cysteine as an amino acid residue at position 26 is substituted by valine, cysteine as an amino acid residue at position 143 is substituted by serine, and proline as an amino acid residue at position 199 is substituted by leucine, with respect to the amino acid sequence shown in SEQ ID NO: 1.
 - 10. A DNA encoding the protein of any of claims 1 to 9.
- 11. A DNA of either one of followings:

10

- (a) DNA encoding the amino acid sequence shown in SEQ ID NO: 1; and
- (b) DNA encoding an amino acid sequence, which comprises a deletion, substitution and/or addition of one or several amino acids with respect to the amino acid sequence shown in SEQ ID NO: 1, and has light-absorbing properties.
- 12. A DNA having either one of the following nucleotide sequences:
 - (a) the nucleotide sequence shown in SEQ ID NO: 2; and
 - (b) a nucleotide sequence comprising a deletion, substitution and/or addition of one or several nucleotides with respect to the nucleotide sequence shown in SEQ ID NO: 2, and encoding a protein having light-absorbing properties.
- 13. A DNA having the nucleotide sequence shown in any one of SEQ ID NOS: 12, 14, 16, 18, 20, or 22.
- 14. A recombinant vector having the DNA of any of claims 10 to 13.
- 15. A transformant having the DNA of any of claims 10 to 13 or the recombinant vector of claim 14.
- 16. A fusion protein composed of the chromoprotein of any of claims 1 to 9 and another protein.
 - 17. A method for analyzing a physiologically active substance, which is characterized in that the FRET (fluorescence resonance energy transfer) method is applied using the chromoprotein of any of claims 1 to 9 as an acceptor protein.
- 18. A light-absorbing reagent kit comprising the chromoprotein of any of claims 1 to 9, the DNA of any of claims 10 to13, the recombinant vector of claim 14, the transformant of claim 15, or the fusion protein of claim 16.

Fig. 1

KGr 20uM

Abs




Fig. 2





Fig. 3

KGr A28G,E41M,C145S,T158I



Flg. 4

Y64L

abs




Fig. 5




Fig. 6




Fig. 7




Fig. 8




Fig. 9




Fig. 10




Fig. 11





Fig. 12



INTERNATIONAL SEARCH REPORT

International application No.

			PCT/J	203/07336
A. CLAS	SIFICATION OF SUBJECT MATTER			
Int	.Cl7 Cl2N15/12, 1/21, 5/10, CO	7K14/435, 19/0	0, G01N21	/78
		•		• •
According	to International Patent Classification (IPC) or to both n	ational classification and	IPC	
	OS SEARCHED			
Minimum o	focumentation searched (classification system followed	by classification symbol	s)	
int	.C1' C12N15/00-15/90, 1/21, 5/ G01N21/78	10, C07K14/00-	14/825, 1	9/00,
	GOINEII 10			
	· · · · · · · · · · · · · · · · · · ·		· · · · · ·	
Documenta	tion searched other than minimum documentation to th	e extent that such docum	ents are included	in the fields searched
			·	
Electronic	data base consulted during the international search (nan	ne of data base and, where	e practicable, sea	rch terms used)
MEDI	LINE(STN), WPI/BIOSIS(DIALOG), Bank/EMBL/DDBJ/GeneSeq, SwissPr	JSTPlus (JOIS)		• •
Geni	sank, bribil, bbbo, Geneseq, Swissri	ot/Pik/Genesed	I	
			<u> </u>	· · · · · ·
C. DOCU	MENTS CONSIDERED TO BE RELEVANT	٠.	·	
Category*	Citation of document, with indication, where a			Relevant to claim No.
Χ.	Atsushi MIYAWAKI, "Shiho Dob	utsu to Keiko	Tanpaku-	1-18
	shitsu", Midoriishi, March, 1	2002, No.13, p	ages	
A	WO 01/27150 A2 (CLONTECH LAI	BORATORIES INC	.),	1-18
	19 April, 2001 (19.04.01), 6 EP 1305412 A2			
	& EF 1303412 A2			
	::			• • •
			- 1	
٠,				
٠.				
Furth	er documents are listed in the continuation of Box C.	See patent family	annex.	······································
* Specia	categories of cited documents:			mational filing date or
"A" docum	ent defining the general state of the art which is not	priority date and no	t in conflict with th	e application but cited to
"E" earlier	ered to be of particular relevance document but published on or after the international filing			erlying the invention saimed invention cannot be
"L" docum	ent which may throw doubts on priority claim(s) or which is	considered novel or	cannot be consider	red to involve an inventive
cited to	establish the publication date of another citation or other		lar relevance; the o	laimed invention cannot be
	reason (as specified) ent referring to an oral disclosure, use, exhibition or other	considered to involve		when the document is documents, such
	ent published prior to the international filing date but later e priority date claimed	combination being of document member of	obvious to a person	skilled in the art
	actual completion of the international search	Date of mailing of the i	Otemational seam	th remort
	une, 2003 (27.06.03)	15 July, 2		
Name and -	railing address of the ISAI	4.10.11.4.22	`	· · · · · · · · · · · · · · · · · · ·
	mailing address of the ISA/ nese Patent Office	Authorized officer		
		* **		
Facsimile N	o.	Telephone No.		